WO1999059997A1 - Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes - Google Patents
Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes Download PDFInfo
- Publication number
- WO1999059997A1 WO1999059997A1 PCT/DK1999/000266 DK9900266W WO9959997A1 WO 1999059997 A1 WO1999059997 A1 WO 1999059997A1 DK 9900266 W DK9900266 W DK 9900266W WO 9959997 A1 WO9959997 A1 WO 9959997A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- phenyl
- spiro
- triaza
- oxo
- alkyl
- Prior art date
Links
- 0 CC1(C(*)CN(C)*)N(*)C(*)N(*)C1=O Chemical compound CC1(C(*)CN(C)*)N(*)C(*)N(*)C1=O 0.000 description 4
- IRTSOBMFCMPSGD-UHFFFAOYSA-N NC(NCCCCCN(CN(C12CCN(Cc3cccc4c3cccc4)CC1)c1ccccc1)C2=O)=N Chemical compound NC(NCCCCCN(CN(C12CCN(Cc3cccc4c3cccc4)CC1)c1ccccc1)C2=O)=N IRTSOBMFCMPSGD-UHFFFAOYSA-N 0.000 description 1
- FAALALNQQPJDPE-LJAQVGFWSA-N NC([C@H](CCCNC(N)=N)NC(CNC(CNC(CN(CN(C12CCN(Cc3c(cccc4)c4ccc3)CC1)c1ccccc1)C2=O)=O)=O)=O)=O Chemical compound NC([C@H](CCCNC(N)=N)NC(CNC(CNC(CN(CN(C12CCN(Cc3c(cccc4)c4ccc3)CC1)c1ccccc1)C2=O)=O)=O)=O)=O FAALALNQQPJDPE-LJAQVGFWSA-N 0.000 description 1
- OYONAAKOYXNOGK-UHFFFAOYSA-N O=C(CN(CN(C12CCN(Cc3c(cccc4)c4ccc3)CC1)c1ccccc1)C2=O)NCc1ccccc1 Chemical compound O=C(CN(CN(C12CCN(Cc3c(cccc4)c4ccc3)CC1)c1ccccc1)C2=O)NCc1ccccc1 OYONAAKOYXNOGK-UHFFFAOYSA-N 0.000 description 1
- BERBJNLBVOVTAM-UHFFFAOYSA-N OC(CN(CN(C12CCN(Cc3cccc4c3cccc4)CC1)c1ccccc1)C2=O)=O Chemical compound OC(CN(CN(C12CCN(Cc3cccc4c3cccc4)CC1)c1ccccc1)C2=O)=O BERBJNLBVOVTAM-UHFFFAOYSA-N 0.000 description 1
- IDTOZWPPPJHQCO-UHFFFAOYSA-N OC(CNC(CN(CN(C12CCN(Cc3cccc4c3cccc4)CC1)c1ccccc1)C2=O)=O)=O Chemical compound OC(CNC(CN(CN(C12CCN(Cc3cccc4c3cccc4)CC1)c1ccccc1)C2=O)=O)=O IDTOZWPPPJHQCO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
Definitions
- the present invention relates to use of small organic compounds acting as opioid receptor ligands for the treatment of vasomotor disturbances.
- the present invention relates to the compounds of the general formula la or lb for the
- the present invention also embraces pharmaceutical compositions comprising these compounds and methods of using the compounds and their pharmaceutical composi-
- a "hot flush” is a sudden transient sensation ranging from warmth to intense heat and typically accompanied by flushing and perspiration. It is the classic sign of the
- nociceptin a novel heptadecapeptide, nociceptin.
- Nociceptin and analogues thereof have been disclosed in WO 97/07212 , EP 813065 and in WO 97/07208.
- These peptides and inhibitors thereof are said to be useful for antagonising physiologic effects of an opioid in an animal, and for treating/preventing a disease related to: hyperalgesia, neuroendocrine secretion, stress, locomotor activity, anxiety etc.
- triaza-spiro compounds are vasodilating agents and morphinelike analgesics as disclosed in US 3,238,216 and US 3,155,670 by Janssen.
- the present invention provides a compound of the formula la or lb as disclosed below or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of Type II diabetes, septic shock, inflammation, incontinence and vasomotor disturbances, in particular the peripheral vasomotor effects known as hot flushes or hot flashes.
- the present invention relates to use of a small organic compound acting as an opioid receptor ligand for the preparation of a pharmaceutical composition for the treatment of a disease selected from migraine, non insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation, incontinence, vasomotor disturbances, in particular the peripheral vasomotor effects known as hot flushes or hot flashes and/or for alleviating symptoms of drug withdrawal, in particular abstinence symptoms occurring during withdrawal from abusive drugs.
- the invention relates to use of a small organic compound acting as a Nociceptin receptor ligands with a molecular weight of less than 1000 or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
- the invention relates to use of small organic compounds acting as Nociceptin receptor ligand with a molecular weight less than 600 or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
- the invention relates to use of a small organic compound acting as a Nociceptin receptor ligand with less than 5 amide bonds or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
- the invention relates to use of a small organic compound acting as a Nociceptin receptor ligands wherein said compound has no amide bonds or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
- the invention relates to use of a compound wherein said compound comprises a triaza-spiro compound acting as a Nociceptin receptor ligand or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
- the invention relates to use of a small organic compound acting as a Nociceptin receptor ligand with an IC 50 less than 1 ⁇ M or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
- the invention relates to a compound of the general formula
- R 1 is phenyl, arylalkyl or thienyl, optionally substituted with one or more of halo- gene, cyano, nitro, trifluoromethyl, C ⁇ -alkyl, hydroxy, C ⁇ -alkoxy or NR 6 R 8 wherein R 6 and R 8 independently are hydrogen or C ⁇ -alkyl, or R 1 is C ⁇ -alkyi; R 2 is aminophenyl, C ⁇ s-monoalkylaminophenyl, C ⁇ -dialkylaminophenyi, cyanophenyl, C 2.6 -alkylphenyl, naphthyl, tetrahydronaphthyl, anthryl, furanyl, indanyl, indolyl, isoindolyl, benzothienyl, benzofuranyl, coumarinyl, said groups may be substituted with one or more of halogen, cyano, nitro, trifluoromethyl, C ⁇ -alkyl,
- R 2 is phenyl, phenoxy, benzodioxinyl or cyanodiphenylmethyl, any of which may be substituted with one or more of halogen, cyano, nitro, trifluoromethyl, C ⁇ -alkyl, hydroxy, C ⁇ -alkoxy, C(0)R 7 , wherein R 7 is -OH, C ⁇ -alkoxy or -NR 12 R 13 , wherein R 12 and R 13 independently are hydrogen or C ⁇ s alkyl, provided that R 1 is not phenyl, R 3 is not methyl or hydrogen or R 4 is not hydrogen, acetyl, methyl, hy- droxymethyl, ethyl, 2-cyanoethyl, propionyl or methoxymethyl;
- R 3 is hydrogen, C ⁇ -alky!, phenyl, benzyl or acetyl;
- R 4 is hydrogen or (CH 2 ) m -(CHR 9 )-(CH 2 )p-AR 11 , wherein m and p independently are 0-4 and R 9 is hydrogen, C ⁇ -alkyl, phenyl or arylalkyl, R 11 is C ⁇ -alkyl, hydroxy, C.,.
- R 5 is hydrogen or C ⁇ -alkyl
- z is CHR wherein R 1 is hydrogen, C ⁇ -alkyl, phenyl or arylalkyl - or z is C 2 -8 alkylene, C 2 . 8 -alkenylene or C 2 . 8 -alkynyiene;
- n 1 or 2 or a pharmaceutically acceptable salt thereof.
- R is phenyl, arylalkyl or thienyl, optionally substituted with one or more of halogene, cyano, nitro, trifluoromethyl, C ⁇ -alkyl, hydroxy, C ⁇ -alkoxy or NR 6 R 8 wherein R 6 and R 8 independently are hydrogen or C, . 6 -alkyl, or R 1 is C ⁇ -alkyl.
- R 2 is aminophenyl, C ⁇ -monoalkylaminophenyl, C ⁇ -dialkylaminophenyl, cya- nophenyl, C 2 . 6 -alkylphenyl, naphthyl, tetrahydronaphthyl, furanyl, indanyl, ben- zothienyl, benzofuranyl, said groups may be substituted with one or more of halo- gene, cyano, nitro, trifluoromethyl, C ⁇ -alkyl, hydroxy, C ⁇ -alkoxy, C(0)R 7 , wherein R 7 is -OH, -NR 12 R 13 , wherein R 2 and R 13 independently are hydrogen or C ⁇ e alkyl , or C ⁇ -alkoxy or R 2 is phenyl provided that R 1 is not phenyl, R 3 is not methyl or hydrogen and R 4 is not hydrogen, acetyl, methyl, hydroxy methyl, ethyl, 2-
- R 3 is hydrogen, C ⁇ -alkyl, phenyl, benzyl or acetyl.
- R 4 is hydrogen or (CH 2 ) m -(CHR 9 )-(CH 2 )p-AR 11 , wherein m and p independently are 0-4 and R 9 is hydrogen, C ⁇ -alkyl, phenyl or arylalkyl, R 11 is C ⁇ -alkyl, hydroxy, C, .
- R 5 is hydrogen or C 1 . 4 -alkyl.
- z is CHR 10 wherein R 10 is hydrogen, C ⁇ -alky!, phenyl or arylalkyl - or z is C 2.8 - alkylene, C 2 . 8 -alkenylene or C 2 . 8 -alkynylene.
- n 1 or 2 or a pharmaceutically acceptable salt thereof.
- R is C ⁇ -alkyl, phenyl, arylalkyl or thienyl.
- R 2 is aminophenyl, C L e-monoalkylaminophenyl, C ⁇ -dialkylaminophenyl, cyanophenyl, C 2 . 6 -alkylphenyl, naphthyl, tetrahydronaphthyl, furanyl, indanyl, benzothienyl, benzofuranyl, said groups may be substituted with one or more of halogen, cyano, nitro, trifluoromethyl, C,. 6 -alkyl, hydroxy, C ⁇ -alkoxy, C(0)R 7 , wherein R 7 is -OH, - NR 12 R 13 , wherein R 12 and R 13 independently are hydrogen or C,. 6 alkyl, or
- R 2 is cyanophenyl or naphthyl, said groups may be substituted with one or more of fluorine, chlorine, bromine, cyano, nitro, trifluoromethyl, C ⁇ -alkyl, hydroxy, C ⁇ - alkoxy, C(0)R 7 , wherein R 7 is -OH, C ⁇ -alkoxy or -NR 12 R 13 wherein R 12 and R 13 independently are hydrogen or C,_ 6 alkyl.
- n is 2.
- Another preferred embodiment of the invention comprises compound la wherein R ⁇ R 2 , R 3 , R 4 , R 5 , z and n are defined as above.
- R 1 is phenyl
- the invention comprises use of a compound of the general formula
- R 1 is phenyl, arylalkyl or thienyl, optionally substituted with one or more of halo- gen, cyano, nitro, trifluoromethyl, C 1 6 -alkyl, hydroxy, C ⁇ -alkoxy or NR 6 R 8 wherein R 6 and R 8 independently are hydrogen or C ⁇ -alkyl, or R 1 is C,.
- R 2 is phenyl, phenoxy, benzodioxinyl, cyanodiphenylmethyl, aminophenyl, C ⁇ - monoalkylaminophenyl, naphthyl, tetrahydronaphthyl, anthryl, furanyl, indanyl, indolyl, isoindolyl, benzothienyl, benzofuranyl, coumari- nyl, said groups may be substituted with one or more of halogen, cyano, nitro, trifluoromethyl, C ⁇ -alkyl, hydroxy, C.,. 6 -alkoxy, C(0)R 7 , wherein R 7 is -OH, C ⁇ - alkoxy or -NR 12 R 13 , wherein R 12 and R 13 independently are hydrogen or C _ 6 alkyl;
- R 3 is hydrogen, C.,_ 6 -alkyl, phenyl, benzyl or acetyl;
- R 4 is hydrogen or (CH 2 ) m -(CHR 9 )-(CH 2 )p-AR 11 , wherein m and p independently are 0-4 and R 9 is hydrogen, C 1-6 -alkyl, phenyl or arylalkyl, R 11 is C ⁇ -alkyl, hydroxy, C g-alkoxy, guanidino, an amino acid residue or a 2-4 peptidyl residue with a C- terminal group consisting of either OCH 3 , or NH 2 ; R 11 can also be a group NR 1 R 15 wherein R 14 and R 15 independently are hydrogen, C ⁇ alkyl, (CH 2 )qR ) 1 16 where q can be 0 to 6 and R 16 can be a C3-C7 membered cycloalkyl ring, an optionally substituted aromatic or heteroaromatic ring, an aliphatic ring containing one or more heteroatoms, an alkoxy or aryloxy group, an amino or a
- R 5 is hydrogen or C ⁇ -alkyl
- z is CHR 10 wherein R 10 is hydrogen, C ⁇ -alkyl, phenyl or arylalkyl - or z is C 2.8 - alkylene, C 2.8 -alkenylene or C 2 . 8 -alkynylene;
- n is 1 or 2 or a pharmaceutically acceptable salt thereof for the treatment of migraine, non insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation, incontinence and/or vasomotor disturbances, in particular the peripheral vasomotor effects known as hot flushes or hot flashes.
- composition in another embodiment of the invention is in a form suitable for oral, nasal, transdermal, pulmonal, or parenteral administration.
- the compound of the formula la or lb is administered as a dose in the range from about 0.01 to about 5000 mg per patient per day, preferably from about 1 to about 1000 mg per patient per day, especially from about 10 to about 100 mg per patient per day, e.g. about 100 mg per patient per day.
- the invention in a fourth aspect relates to a method for the treatment or prevention of migraine, Type II diabetes, sepsis, inflammation, incontinence and/or vasomotor disturbances, in particular the peripheral vasomotor effects known as hot flushes or hot flashes, the method comprising administering to a patient in need thereof an effective amount of compound of the formula la or lb or a pharmaceutically acceptable salt thereof.
- the invention relates to a pharmaceutical composition
- a pharmaceutical composition comprising triaza-spiro compounds with high affinity to the nociceptin receptor, or a pharmaceutically acceptable salt thereof.
- the invention relates to a method of treatment symptoms of drug withdrawal, in particular abstinence symptoms occurring during withdrawal from abusive drugs.
- the effective such as the therapeutically effective amount of a compound of the formula la or lb will depend upon the mode of administration, on the therapy desired, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in charge.
- the term "patient” comprises any mammal which may benefit from treatment or prevention of vasomotor disturbances, such as a human, especially if the mammal is a female, such as a woman. However, “patient” is not intended to be limited to a woman.
- small organic compounds refers to compounds with a molecular weight below 1000 and with less than 5 amide bonds or no amide bonds.
- triaza-spiro represents a compound of formula with various substituents as defined above.
- high affinity represents an IC 50 below 1 ⁇ M.
- arylalkyl refers to a straight or branched saturated carbon chain containing from 1 to 6 carbons substituted with an aromatic hydrocarbon; such as benzyl, phenethyl, 3-phenylpropyl, 1-naphtylmethyl, 2-(1- naphtyl)ethyl and the like.
- C ⁇ -alky! groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, butyl, iso- butyl, sec-butyl, tert-butyl, pentyl, iso-pentyl, hexyl, iso-hexyl and the like.
- C L g-alkoxy alone or in combination is intended to include those groups of the designated length in either a linear or branched or cyclic configuration linked thorugh an ether oxygen having its free valence bond from the ether oxygen.
- linear alkoxy groups are methoxy, ethoxy, propoxy, butoxy, pentoxy and hexoxy.
- branched alkoxy are isopropoxy, sec-butoxy, tert-butoxy, isopentoxy and isohexoxy.
- cyclic alkoxy are cyclopropyloxy, cyclobutyloxy, cyclopentyloxy and cyclohexyloxy.
- halogen means fluorine, chlorine, bromine or iodine.
- amino acid residue or peptidyl residues is also meant to comprise naturally occurring or synthetically produced amino acids linked to the compound by an amide bond.
- C 2 8 .-alkylene represent a branched or straight alkyl group having from one to the specified number of carbon atoms.
- Typical C 2 _ 8 - alkylene groups include, but are not limited to, ethylene, n-propylene, iso- propylene, butylene, iso-butylene, sec-butylene, tert-butylene, pentylene, iso- pentylene, hexylene, iso-hexylene and the like.
- C 2 . 8 .-alkenylene represents an olefinicaily unsatu- rated branched or straight group with at least one double bond.
- groups include, but are not limited to, vinyl, 1 -propenylene, allylene, iso- propenylene, 1 ,3-butadienylene, 1 -butenylene, hexenylene, pentenylene, and the like.
- C 2 . 8 .-alkynylene represent an unsaturated branched or straight group having at least one triple bond. Examples of such groups include, but are not limited to, 1 -propynylene, 1 -butynylene, 2-butynylene, 1 - pentynylene, 2-pentynylene and the like.
- ligand is also meant to comprise a compound with agonistic, partial agonistic or antagonistic activity specifically binding to receptor proteins.
- treatment is also meant to comprise prophylactic treatment.
- the preparation of compounds of formula la may include, but are not limited to the following methods:
- a compound of formula (II) wherein R 1 , R 3 , R R 5 and n are as defined above may be allowed to react with a compound of formula (III), wherein R 2 and z are defined as above and X is a suitable leaving group such as halogen, p-toluene sulphonate or mesylate.
- This alkylation reaction may be carried out in a solvent such as acetone, dibutylether, 2-butanone, methyl ethyl ketone, ethyl acetate, tetrahydrofuran (THF) or toluene in the presence of a base e.g. sodium hydride and a catalyst, e.g.
- a compound of formula (II) wherein R 1 , R 3 , R 4, R 5 , and n are as defined above may be allowed to react with an aldehyde of formula (IV), wherein R 2 is as defined above and the linker y is one C-atom shorter than linker z, where z is as defined above, to form an imine of formula (V).
- the reaction may be carried out in a suitable solvent like a lower aliphatic alcohol as e.g. ethanol or an ether as e.g. tetrahydrofuran or a mixture of these.
- the formed iminium derivative of formula (V) is then reduced to an amine of formula (la) by the addition of a suitable reducing agent, e.g. a hydride as sodium cyanoborohydride or sodium borohydride in e.g. 1 to 120 h at 20° C to reflux temperature.
- a suitable reducing agent e.g. a hydride as sodium cyanoborohydride or sodium
- Compounds of formula (la) may also be prepared in a parallel fashion using solid phase technology, e.g. as described by F. Zaragoza and S.V. Petersen, Tetrahedron, 52, 10823 (1996).
- R 4 in a compound of formula (II) is replaced by (CH 2 ) m -(CHR 9 )-(CH 2 ) p -C(0)R 7b , wherein m, p and R 9 are as defined above and R 7 is a resin-O- or a resin-NH-residue.
- a compound of formula (VI) wherein R ⁇ R 2 , R 3 , R 5 , z and n are as defined above, may be deprotonated at N3 with a suitable base, as sodium hydride, n-butyl lith- ium or potassium tert.-butoxide in an aprotic solvent as e.g. dimethyl formamide or dimethylsulfoxide and subsequently allowed to react with a reagent of formula (VII), wherein R 4 and X are as defined above.
- the reaction may be carried out at temperatures from 0 °C to reflux temperature, preferably at room temperature in 1 to 24 hours, to form a compound of formula (la).
- a compound of formula (la) may further be synthesized by allowing a compound of formula (VIII), wherein R 1 , R 2 , R 3 , R 5 , R 9 , m, p, n an z are as described above, to react with a compound of formula (IX), in which the R 11 group bears a residue which is coupled to a resin and may be subsequently cleaved from the resin as an ester or amide moiety.
- the coupling reaction between (VIII) and (IX) may be carried out in a suitable solvent as e.g. dimethyl formamide or N-methyl pyrrolidone using e.g.
- the compound of the formula la or lb may be prepared in the form of pharmaceutically acceptable salts such as base or acid addition salts, especially acid-addition salts, including salts of organic acids and min- eral acids.
- pharmaceutically acceptable salts such as base or acid addition salts, especially acid-addition salts, including salts of organic acids and min- eral acids.
- salts include salts of organic acids such as formic acid, fumaric acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, succinic acid, malic acid, maleic acid, tartaric acid, citric acid, benzoic acid, salicylic acid and the like.
- Suitable inorganic acid-addition salts include salts of hydrochloric, hydrobromic, sulphuric and phosphoric acids and the like.
- Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science. 66
- Also intended as pharmaceutically acceptable acid addition salts are the hydrates which the present compound of the formula la or lb are able to form.
- the acid addition salts may be obtained as the direct products of compound synthesis.
- the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.
- the compounds of the formula la or lb of this invention may form solvates with standard low molecular weight solvents using methods known to a person skilled in the art.
- the compound of the formula la or lb may be administered in pharmaceutically acceptable acid addition salt form .
- Such salt forms are believed to exhibit approximately the same order of activity as the free base forms.
- a pharmaceutical composition for use in accordance with the present invention comprises, one or more compound of the formula la or lb as active ingredient(s), or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
- compositions containing compounds of the formula la or lb of the present invention may be prepared by conventional techniques, e.g. as described in Remington: The Science and Practise of Pharmacy. 19 th Ed., 1995.
- the compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.
- compositions include Compound of formula la or lb or a pharmaceutically acceptable acid addition salt thereof, associated with a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container.
- a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container.
- the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container.
- the carrier When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound.
- the active compound can be adsorbed on a granular solid container for example in a sachet.
- suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatine, lactose, terra alba, sucrose, cyclodextrin, amylose, magnesium stearate, talc, gelatine, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone.
- the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
- the formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents.
- the formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
- compositions can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring substances and the like, which do not deleteriously react with the active compounds.
- the route of administration may be any route, which effectively transports the active compound to the appropriate or desired site of action, such as oral, nasal, pulmonary, transdermai or parenteral e.g. rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment.
- the preparation may be tabletted, placed in a hard gelatine capsule in powder or pellet form or it can be in the form of a troche or lozenge.
- a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
- the preparation may contain a compound of formula la or lb dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application.
- the carrier may contain additives such as solubilizing agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes.
- injectable solutions or suspensions preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
- Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application.
- Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or po- tato starch.
- a syrup or elixir can be used in cases where a sweetened vehicle can be employed.
- a typical tablet which may be prepared by conventional tabletting techniques may contain:
- Active compound 100 mg Colloidal silicon dioxide (Aerosil) 1.5 mg Cellulose, microcryst. (Avicel) 70 mg Modified cellulose gum (Ac-Di-Sol) 7.5 mg Magnesium stearate Ad.
- mice Male Sprague Dawley rats ( 300 ⁇ 25 g) were anaesthetized with pentobarbital sodium (50 mg/kg i.p.) and polyethylene catheters were positioned in both femoral veins for the intravenous administration of drugs, such as nociceptin and analogues, and into the left femoral artery in order to measure arterial blood pressure and heart rate.
- drugs such as nociceptin and analogues
- the trachea was cannulated with polyethylene tubing and the rat was pithed, ventilated and drug treated as described by Nuki Y. et al. (Effects of Dorsal Rhizotomy on Depressor Response to Spinal Cord Stimulation Mediated by Endogenous Calcitonin Gene-related Peptide in the Pithed Rat. J. Neurosurg. 1993; 79:899-904).
- HPLC-MS analyses were performed on a PE Sciex API 100 LC/MS System using Method 1 : a WatersTM 3 mm x 150 mm 3.5 ⁇ C-18 Symmetry column and positive ionspray with a flow rate of 20 ⁇ L/minute.
- Method 2 a YMC ODS-A 120 A s - 5 ⁇ 3 mm x 50 mm column and positive ionspray with a flow rate of 20 ⁇ L/minute.
- the column was eluted with a linear gradient of 5-90% A, 85-0% B and 10% C in 7.5 minutes at a flow rate of 1.5 ml/min.
- solvent A acetonitrile
- solvent B water
- solvent C 0.5% trifluoroacetic acid in water).
- M.p. is melting point and is given in °C and is not corrected.
- Column chromatography was carried out using the technique described by W.C. Still et al,
- the resin was agitated with 20% piperidine in N,N- dimethylformamide (10 ml) for 30 minutes. The solution was removed by suction, the resin was washed with N,N-dimethylformamide (2x 10 ml), dichloromethane (4x 10 ml) and methanol (3x 10 ml) and dried. This yielded the Wang resin (2.53 g) with attached 3-carboxy-1-phenyl-1 ,3,8-triazaspiro[4.5]decan-4-one (0.67 mmol/g).
- the resin was drained, washed with dimethyl sulfoxide (2x 1 ml), dichloromethane (4x 1 ml) and methanol (2x 1 ml).
- a solution of sodium methoxide (0.009 mmol) in a mixture of tetrahydrofu- ran/methanol 4:1 (2 ml) was added to the resin and the suspension was agitated at 50 °C for 16 h.
- the mixture was neutralized by addition of a solution of acetic acid (0.01 mmol) in a mixture of tetrahydrofuran/methanol 4:1 (1 ml), the solution was drained and the resin was washed with tetrahydrofuran (1 ml).
- the combined filtrates were concentrated in vacuo to yield the title compounds.
- the formed precipitate was collected by filtration, washed successively with water (800 ml), toluene (600 ml) and icecold acetone (2 X 200 ml) and dried affording the title compound as a powder (191.20 g, 68% yield).
- Teflon tube equipped with a frit on a mechanical shaker.
- the resin was allowed to swell in dimethyl formamide (1.5 ml) for 1 h.
- the solvent was removed by suction and the resin was agitated with 20% pipehdine in N,N-dimethylformamide (1.5 ml) for 30 minutes.
- the solution was removed by suction and the resin was washed with N,N-dimethylformamide (3x 1.5 ml).
- the resin was filtered and washed with dimethylformamide (2 x 1.5 ml), dichloromethane (4 x 1.5 ml), methanol (2 x 1.5 ml) and tetrahydrofuran/methanol 4:1 (2 x 1.5 ml).
- a solution of sodium methoxide (0.009 mmol) in a mixture of tetrahydrofuran/methanol 4:1 (2 ml) was added to the resin and the suspension was agitated at 50 °C for 16 h.
- Rink Amide (AM) resin (0.69 mmol/g, pur- chased from Novabiochem) was suspended in piperidine/N,N-dimethylformamide (20%) (all volumes are calculated as 10 ml/gram of resin) and shaken on a mechanical shaking apparatus for 0.5 h.
- the resin was filtered, rinsed with N,N- dimethylformamide, suspended in piperidine/N,N-dimethylformamide (20%) and shaken for 0.5 h.
- the resin was filtered and washed as follows: 3 x N,N- dimethylformamide /water (90%), 2 x ethanol, 3 x N,N-dimethylformamide, 5 x methylene chloride.
- the resin was dried in vacuo and suspended in N,N- dimethylformamide.
- Fmoc-Arg(Pbf).OH 1.7 g, 01.7 mmol, 4 equivalents
- EDAC N-(3-dimethylaminopropyl)-N'-ethyl carbodiimide hydrochloride
- HOBT 1-hydroxybenzotriazole
- the resin was filtered and washed successively with 3 x N,N-dimethylformamide /water (90%), 3 x N,N-dimethylformamide, 3 x methylene chloride, was suspended in piperidine/N,N-dimethylformamide (20%) and shaken for 0.5 h.
- the resin was filtered and washed as follows: 3 x N,N-dimethylformamide /water (90%), 2 x ethanol, 3 x N,N-dimethylformamide, 5 x methylene chloride.
- the resin was dried in vacuo and suspended in N,N-dimethylformamide and (8- naphthalen-1-ylmethyl-4-oxo-1-phenyi-1 ,3,8-triaza-spiro[4.5]dec-3-yl)-acetic acid (1.08 g, 2.51 mmol, 3.6 equivalents) was added followed by EDAC (0.47 g, 2.51 mmol, 3.6 equivalents), HOBT (0.33 g, 2.51 mmol, 3.6 equivalents) and the reac- tion was allowed to stir at room temperature for 20 h.
- the resin was filtered and washed 3 x N,N-dimethylformamide /water (90%), 3 x N,N-dimethylformamide, 3 x methylene chloride and dried in vacuo.
- the resin was suspended in trifluoroacetic acid/water (95%) and shaken for 2 h.
- the filtrate was collected and added dropwise to cyclohexane/ether (50%) after which a white precipitate was observed.
- This white solid was collected and washed 3 x cyclohexane/ether (50%) with the aid of a centrifuge. This was dissolved in a minimum amount of acetonitrile/water (10%) and lyophiiized affording the title compound (273 mg, 50% yield), as a white powder.
- HPLC retention time 11.01 minutes (5 ⁇ m C18 4 x 250 mm column, eluting with a 20-80 % gradient of 0.1 % trifluoroacetic acid/acetonitrile and 0.1 % trifluoroacetic acid/water over 30 minutes at 35 °C).
- This compound was prepared and purified analogously to EXAMPLE 8 using Rink Amide (AM) Resin (0.69 mmol/g) (0.200 g, 0.138 mmol, 1 equivalent), Fmoc- .D-Arg(Pbf).OH (0.358 g, 0.552 mmol, 4 equivalents) to yield the title compound (73 mg, 59% yield) as a white powder. This powder was assumed to be salted with two equivalents of trifluoroacetic acid.
- AM Rink Amide
- the resin was suspended in dimethylformamide, treated with (8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl)- acetic acid (0.274 g, 0.640 mmol), 1-hydroxybenzotriazole (0.099 g, 0.640 mmol) and N,N'-diisopropylcarbodiimide (0.081 g, 0.640 mmol).
- the reaction was al- lowed to shake for 20 h at room temperature.
- the resin was filtered, suspended in dimethylsulfoxide and heated to 40 °C for 1 h.
- the resin was again filtered, suspended in dimethylsulfoxide (8 ml) and heated to 40 °C for 1 h.
- the resin was filtered and washed as follows: 3 x dimethylformamide/water (90/10) (8 ml); 3 x dimethylformamide (8 ml); 3 x dichloromethane (8 ml) and air-dried.
- the resin was treated with trifluoroacetic acid/water (95/5) (8 ml) for 1 h at room temperature. The filtrate was collected and concentrated in vacuo to give the desired product.
- EXAMPLE 10A 2-. SV[2-(8-Naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1.3.8-triaza-spiro[4.51dec-3-yn- acetylamino]-5-ureido-pentanoic acid amide
- Rink Amide (AM) resin (Novabiochem) (0.200 g, 0.138 mmol) was suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature. The resin was filtered and rinsed with dimethylformamide (8 ml) and again suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for
- the resin was filtered and rinsed with dimethylformamide (8 ml) and again suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature; the resin was washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml). The resin was suspended in dimethylformamide (8 ml); (8-naphthalen-1-
- the resin was filtered and washed as follows: 3 x dimethylforma- mide/water (90/10) (8 ml); 3 x dimethylformamide (8 ml); 3 x dichloromethane (8 ml) and air-dried.
- the resin was treated with trifluroacetic acid/water (95/5) (8 ml) for 2 h at room temperature.
- the filtrate was collected and concentrated in vacuo to give the desired product.
- Rink Amide (AM) resin (Novabiochem) (0.200 g, 0.138 mmol) was suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room tem- perature.
- the resin was filtered and rinsed with dimethylformamide and again suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature; the resin was washed as follows: 3 x dimethylforma- mide/water (90/10) (8 ml), 3 x dimethylformamide(8 ml), 3 x dichloromethane.
- the resin was suspended in dimethylformamide (8 mL), L-Fmoc-Arg(Pbf)-OH (0.358 g, 0.552 mmol) and 1-hydroxybenzotriazole (0.085 g, 0.552 mmol) were added. N,N'-diisopropylcarbodiimide (0.071 g, 0.552 mmol) was added and the reaction was allowed to shake for 20 h at room temperature. The resin was filtered and washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml).
- the resin was suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature.
- the resin was filtered and rinsed with dimethylformamide and again suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature; the resin was washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml).
- the resin was suspended in dimethylformamide (8 ml), Fmoc.Gly.OH (0.163 g, 0.552 mmol), 1-hydroxybenzotriazole (0.085 g, 0.552 mmol) and N,N'- diisopropylcarbodiimide (0.071 g, 0.552 mmol) were added. The reaction was allowed to shake 20 h at room temperature. The resin was filtered and washed as follows: 3 x dimethylformamide/water (80/20) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml). The resin was suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature.
- the resin was filtered and rinsed with dimethylformamide and again suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room tem- perature; the resin was washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml).
- the resin was suspended in dimethylformamide (8 ml); (8-naphthaien-1-ylmethyl-4-oxo-1- phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl)-acetic acid (0.269 g, 0.552 mmol), 1- hydroxybenzotriazole (0.085 g, 0.552 mmol) and N,N'-diisopropylcarbodiimide (0.071 g, 0.552 mmol) were added.
- the reaction mixture was allowed to shake at room temperature for 20 h and filtered and washed as follows: 3 x dimethylformamide/water (90/10) (8 ml); 3 x dimethylformamide (8 ml); 3 x dichloromethane (8 ml) and air-dried.
- the resin was treated with trifluoroacetic acid/water (95/5) (8 ml) for 2 h at room temperature.
- the filtrate was collected and added dropwise to cyclohexane/ether at 0 °C to form a white precipitate.
- EXAMPLE 12 5-Guanidino-2-. S 2- ⁇ 2-[2-( 8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1.3.8-triaza- spiro[4.5]dec-3-yl)-acetylamino]-acetylamino ⁇ -acetylamino.-pentanoic acid amide
- Rink Amide (AM) resin (Novabiochem) (0.200 g, 0.138 mmol) was suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room tem- perature.
- the resin was filtered and rinsed with dimethylformamide and again suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature; the resin was washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml).
- the resin was suspended in dimethylformamide (8 ml), L- Fmoc-Arg(Pbf)- OH (0.358 g, 0.552 mmol) and 1-hydroxybenzotriazole (0.085 g, 0.552 mmol) were added. N,N'-diisopropylcarbodiimide (0.071 g, 0.552 mmol) was added and the reaction was allowed to shake for 20 h at room temperature. The resin was filtered and washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethyGformamide (8 ml), 3 x dichloromethane (8 ml).
- the resin was sus- pended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature.
- the resin was filtered and rinsed with dimethylformamide and again suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature; the resin was washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml).
- the resin was suspended in dimethylformamide (8 ml), Fmoc-Gly-Gly-OH (0.195 g, 0.552 mmol), 1-hydroxybenzotriazole (0.085 g, 0.552 mmol) and N,N'- diisopropylcarbodiimide (0.071 g, 0.552 mmol) were added and the reaction was allowed to shake for 20 h at room temperature.
- the resin was filtered and washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml).
- the resin was suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room tem- perature.
- the resin was filtered and rinsed with dimethylformamide and again suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature; the resin was washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml).
- the resin was suspended in dimethylformamide (8 ml); (8-naphthalen-1- ylmethyi-4-oxo-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl)-acetic acid (0.269 g, 0.552 mmol), 1-hydroxybenzotriazole (0.085 g, 0.552 mmol) and N,N'- diisopropylcarbodiimide (0.071 g, 0.552 mmol) were added.
- the reaction mixture was allowed to shake at room temperature for 20 h, filtered and washed as follows: 3 x dimethylformamide/water (90/10) (8 ml); 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml).
- the resin was treated with trifluoroacetic acid/water (95/5) (8 ml) for 2 h at room temperature.
- the filtrate was collected and added dropwise to cyclohexane/diethylether (50/50) at 0 °C to form a white precipitate which was collected and washed with the cyclohexane/diethylether solution. 32.5 mg of product were collected.
- the compound was synthesized using 3-(7-bromo-heptyl)-8-naphthalen-1- ylmethyl-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]decan-4-one, prepared as described in Example 13.
- the 1 ,3-diaminopropyl Wang resin was prepared using the procedure described above.
- N-(2-aminoethyl)-2-(8-naphthalen-1-ylmethyl-4-oxo-1-phenyl- 1 ,3,8-triazaspiro[4.5]dec-3-yl)acetamide dihydrochloride (0.203 g, 0.40 mmol) in dimethylformamide (1.5 ml) was added diisopropylethylamine (0.046 g, 3.6 mmol) and 1-H-pyrazole-1-carboxamidine hydrochloride (0.088 g, 0.60 mmol). The mixture was stirred at room temperature for 1 h and the same amount of 1-H- pyrazole-1-carboxamidine hydrochloride was added.
- Rink Amide (AM) resin (Novabiochem) (0.200 g, 0.138 mmol) was suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature.
- the resin was filtered and rinsed with dimethylformamide (8 ml) and again suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 25 30 min at room temperature; the resin was washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml).
- the resin was suspended in dimethylformamide (8 ml), L Fmoc-Lys(Boc)- OH (0.258 g, 0.552 mmol), 1-hydroxybenzotriazole (0.085 g, 0.552 mmol) and N,N'-diisopropylcarbodiimide (0.071 g, 0.552 mmol) were added and the reaction was allowed to shake for 20 h at room temperature. The resin was filtered and
- the resin was filtered and rinsed with dimethylformamide (8 ml) and again suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature; the resin was washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml).
- the resin was suspended in dimethylformamide (8 ml); (8-naphthalen-1- ylmethyl-4-oxo-1-phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl)-acetic acid (0.269 g, 0.552 mmol), 1-hydroxybenzotriazole (0.085 g, 0.552 mmol) and N,N'- diisopropylcarbodiim.de (0.071 g, 0.552 mmol) were added.
- the reaction mixture was allowed to shake at room temperature for 20 h, filtered and washed as follows: 3 x dimethylformamide/water (90/10) (8 ml); 3 x dimethylformamide; 3 x di- chloromethane (8 ml).
- the resin was treated with trifluoroacetic acid/water (95/5) (8 ml) for 2 h at room temperature.
- the filtrate was collected and added dropwise to heptane/diethylether at 0 °C to form a white precipitate which was collected and washed with the heptane/diethylether solution. 13.7 mg of product were isolated.
Abstract
The present invention relates to use of small organic compounds acting as opioid receptor ligands for the treatment of vasomotor disturbances. In particular the present invention relates to the triazaspiro compounds of general formula (Ia) or (Ib) wherein R1 is selected among phenyl, arylalkyl or thienyl; R2 is selected among aminophenyl, C¿1-6?-monoalkylaminophenyl, C1-6-dialkylaminophenyl, cyanophenyl, C2-6-alkylphenyl, naphthyl, tetrahydronaphthyl, furanyl, indanyl, benzothienyl or benzofuranyl; R?3¿ is hydrogen, C¿1-6?-alkyl, phenyl, benzyl, or acetyl; R?4¿ is hydrogen or (CH¿2?)m-(CHR?9)-(CH¿2)p-AR11; R5 is hydrogen or C¿1-4?-alkyl; z is CHR?10¿ wherein R10 is hydrogen, C¿1-6?-alkyl, phenyl or arylalkyl - or z is C2-8-alkylene, C2-8-alkenylene or C2-8-alkynylene; n is 1 or 2; or a pharmaceutically acceptable salt thereof for the treatment of migraine, non insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation, incontinence and/or vasomotor disturbances, in particular the peripheral vasomotor effects known as hot flushes or hot flashes.
Description
TITLE
Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
5
FIELD OF INVENTION
The present invention relates to use of small organic compounds acting as opioid receptor ligands for the treatment of vasomotor disturbances. In particular the present invention relates to the compounds of the general formula la or lb for the
10 treatment of migraine, non insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation, incontinence and/or vasomotor disturbances, in particular the peripheral vasomotor effects known as hot flushes or hot flashes. The present invention also embraces pharmaceutical compositions comprising these compounds and methods of using the compounds and their pharmaceutical composi-
15 tions.
BACKGROUND OF THE INVENTION
A "hot flush" is a sudden transient sensation ranging from warmth to intense heat and typically accompanied by flushing and perspiration. It is the classic sign of the
20 menopause and the predominant complaint of menopausal women.
A positive correlation between plasma levels of calcitonin gene-related peptide (CGRP) and frequency of hot flushes in women has recently been reported (Chen et al., 1993, Lancet (342) 49), in accordance with the potent vasodilatory effect of CGRP (Brain et al., 1985, Nature, (313) 54-56).
25 Also, a positive correlation between CGRP antagonists and diabetes, septic shock and inflammation has been described ( Feurstein, G, Willette, R and Aiyar, N., 1995, Can. J. Physiol. Pharmacol. 73: 1070-1074).
Recently, a novel heptadecapeptide, nociceptin, was discovered (Meunier et al., 30 1995, Nature (377) 532-535, Reinscheid et al., 1995, Science (270) 792-794).
Nociceptin and analogues thereof have been disclosed in WO 97/07212 , EP 813065 and in WO 97/07208. These peptides and inhibitors thereof are said to be useful for antagonising physiologic effects of an opioid in an animal, and for treating/preventing a disease related to: hyperalgesia, neuroendocrine secretion, stress, locomotor activity, anxiety etc.
Jenck, F et. al. also found, that Orphanin FQ acts as an anxiolytic to attenuate behavioralresponses to stress (PNAS Vol. 94, 1997).
It is well known that triaza-spiro compounds are vasodilating agents and morphinelike analgesics as disclosed in US 3,238,216 and US 3,155,670 by Janssen.
SUMMARY OF THE INVENTION
It has been found that members of a novel group of triaza-spiro compounds have high affinity for nociceptin receptors which make them useful as regulators of peripheral vasomotor effects known as hot flushes. The present invention provides a compound of the formula la or lb as disclosed below or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of Type II diabetes, septic shock, inflammation, incontinence and vasomotor disturbances, in particular the peripheral vasomotor effects known as hot flushes or hot flashes.
Further objects will become apparent from the following description.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to use of a small organic compound acting as an opioid receptor ligand for the preparation of a pharmaceutical composition for the treatment of a disease selected from migraine, non insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation, incontinence, vasomotor disturbances, in particular the peripheral vasomotor effects known as hot flushes or hot flashes and/or for alleviating symptoms of drug withdrawal, in particular abstinence symptoms occurring during withdrawal from abusive drugs.
In another aspect the invention relates to use of a small organic compound acting as a Nociceptin receptor ligands with a molecular weight of less than 1000 or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
In still another aspect the invention relates to use of small organic compounds acting as Nociceptin receptor ligand with a molecular weight less than 600 or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
In yet another aspect the invention relates to use of a small organic compound acting as a Nociceptin receptor ligand with less than 5 amide bonds or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
In a further aspect the invention relates to use of a small organic compound acting as a Nociceptin receptor ligands wherein said compound has no amide bonds or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
In still another aspect the invention relates to use of a compound wherein said compound comprises a triaza-spiro compound acting as a Nociceptin receptor ligand or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
In yet another aspect the invention relates to use of a small organic compound acting as a Nociceptin receptor ligand with an IC50 less than 1μM or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
In a second aspect the invention relates to a compound of the general formula
wherein
R1 is phenyl, arylalkyl or thienyl, optionally substituted with one or more of halo- gene, cyano, nitro, trifluoromethyl, C^-alkyl, hydroxy, C^-alkoxy or NR6R8 wherein R6 and R8 independently are hydrogen or C^-alkyl, or R1 is C^-alkyi; R2 is aminophenyl, C^s-monoalkylaminophenyl, C^-dialkylaminophenyi, cyanophenyl, C2.6-alkylphenyl, naphthyl, tetrahydronaphthyl, anthryl, furanyl, indanyl, indolyl, isoindolyl, benzothienyl, benzofuranyl, coumarinyl, said groups may be substituted with one or more of halogen, cyano, nitro, trifluoromethyl, C^-alkyl, hydroxy,
or -NR 2R13, wherein R12 and R13 independently are hydrogen or C,.6 alkyl or
R2 is phenyl, phenoxy, benzodioxinyl or cyanodiphenylmethyl, any of which may be substituted with one or more of halogen, cyano, nitro, trifluoromethyl, C^-alkyl, hydroxy, C^-alkoxy, C(0)R7, wherein R7 is -OH, C^-alkoxy or -NR12R13, wherein R12 and R13 independently are hydrogen or C^s alkyl, provided that R1 is not phenyl, R3 is not methyl or hydrogen or R4 is not hydrogen, acetyl, methyl, hy- droxymethyl, ethyl, 2-cyanoethyl, propionyl or methoxymethyl;
R3 is hydrogen, C^-alky!, phenyl, benzyl or acetyl;
R4 is hydrogen or (CH2)m-(CHR9)-(CH2)p-AR11, wherein m and p independently are 0-4 and R9 is hydrogen, C^-alkyl, phenyl or arylalkyl, R11 is C^-alkyl, hydroxy, C.,. 6-alkoxy, guanidino, an amino acid residue or a 2-4 peptidyl residue with a C- terminal group consisting of either OCH3, or NH2 ; R11 can also be a group NR14R15 wherein R14 and R15 independently are hydrogen, C,_6 alkyl, (CH2)qR16 where q can be 0 to 6 and R16can be a C3-C7 membered cycloalkyl ring, an optionally substituted aromatic or heteroaromatic ring, an aliphatic ring containing one or more heteroatoms, an alkoxy or aryloxy group, an amino or a guanidino group; A is -CH2 or -C=0; provided that when R11 is an amino acid or peptidyl residue, then A is a -C=0 group;
R5 is hydrogen or C^-alkyl;
z is CHR wherein R1 is hydrogen, C^-alkyl, phenyl or arylalkyl - or z is C 2-8 alkylene, C2.8-alkenylene or C2.8-alkynyiene;
n is 1 or 2 or a pharmaceutically acceptable salt thereof.
In another aspect of the invention R is phenyl, arylalkyl or thienyl, optionally substituted with one or more of halogene, cyano, nitro, trifluoromethyl, C^-alkyl, hydroxy, C^-alkoxy or NR6R8 wherein R6 and R8 independently are hydrogen or C,. 6-alkyl, or R1 is C^-alkyl.
R2 is aminophenyl, C^-monoalkylaminophenyl, C^-dialkylaminophenyl, cya- nophenyl, C2.6-alkylphenyl, naphthyl, tetrahydronaphthyl, furanyl, indanyl, ben- zothienyl, benzofuranyl, said groups may be substituted with one or more of halo- gene, cyano, nitro, trifluoromethyl, C^-alkyl, hydroxy, C^-alkoxy, C(0)R7, wherein R7 is -OH, -NR12R13, wherein R 2 and R13 independently are hydrogen or C^e alkyl , or C^-alkoxy
or R2 is phenyl provided that R1 is not phenyl, R3 is not methyl or hydrogen and R4 is not hydrogen, acetyl, methyl, hydroxy methyl, ethyl, 2-cyanoethyl, propionyl or methoxymethyl.
R3 is hydrogen, C^-alkyl, phenyl, benzyl or acetyl.
R4 is hydrogen or (CH2)m-(CHR9)-(CH2)p-AR11, wherein m and p independently are 0-4 and R9 is hydrogen, C^-alkyl, phenyl or arylalkyl, R11 is C^-alkyl, hydroxy, C,. 6-alkoxy, guanidino, an amino acid residue or a 2-4 peptidyl residue with a C- terminal group consisting of either OCH3, or NH2 ; R11 can also be a group NR14R15 wherein R14 and R15 independently are hydrogen, C^ alkyl, (CH2)qR16 where q can be 0 to 6 and R16 can be a C3-C7 membered cycloalkyl ring, an optionally substituted aromatic or heteroaromatic ring, an aliphatic ring containing one or more heteroatoms, an alkoxy or aryloxy group, an amino or a guanidino group; A is -CH2 or -C=0; provided that when R is an amino acid or peptidyl residue, then A is a -C=0 group.
R5 is hydrogen or C1.4-alkyl.
z is CHR10 wherein R10 is hydrogen, C^-alky!, phenyl or arylalkyl - or z is C2.8- alkylene, C2.8-alkenylene or C2.8-alkynylene.
n is 1 or 2 or a pharmaceutically acceptable salt thereof.
In another embodiment of the invention R is C^-alkyl, phenyl, arylalkyl or thienyl.
In yet another embodiment of the invention R2 is
aminophenyl, CLe-monoalkylaminophenyl, C^-dialkylaminophenyl, cyanophenyl, C2.6-alkylphenyl, naphthyl, tetrahydronaphthyl, furanyl, indanyl, benzothienyl, benzofuranyl, said groups may be substituted with one or more of halogen, cyano, nitro, trifluoromethyl, C,.6-alkyl, hydroxy, C^-alkoxy, C(0)R7, wherein R7 is -OH, - NR12R13, wherein R12 and R13 independently are hydrogen or C,.6 alkyl, or
In still another embodiment of the invention R2 is cyanophenyl or naphthyl, said groups may be substituted with one or more of fluorine, chlorine, bromine, cyano, nitro, trifluoromethyl, C^-alkyl, hydroxy, C^- alkoxy, C(0)R7, wherein R7 is -OH, C^-alkoxy or -NR12R13 wherein R12 and R13 independently are hydrogen or C,_6 alkyl.
In a preferred embodiment of the invention n is 2.
Another preferred embodiment of the invention comprises compound la wherein R\ R2, R3, R4, R5 , z and n are defined as above.
In still another preferred embodiment of the invention R1 is phenyl;
In yet another preferred embodiment of the the invention the compounds are selected from the following:
(4-Oxo-8-phenethyl-1-phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl)-acetic acid methyl ester, (1a)
{8-[2-(1 ,3-Dioxo-1 ,3-dihydro-isoindol-2-yl)-ethyl]-4-oxo-1-phenyl-1 ,3,8-triaza- spiro[4.5]dec-3-yi}-acetic acid methyl ester, (1b)
[8-(3-Cyano-3,3-diphenyl-propyl)-4-oxo-1-phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl]- acetic acid methyl ester, (1c)
[8-(4-Nitro-benzyl)-4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester, (1d)
[4-Oxo-l -phenyl-8-(3-phenyi-propyl)-1 , 3, 8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester, (1e) [4-Oxo-8-(3-phenoxy-propyl)-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester, (1f)
[4-Oxo-8-(4-phenoxy-butyl)-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester, (1g)
[8-(2,3-Dihydro-benzo[1 ,4]dioxin-2-ylmethyl)-4-oxo-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]dec-3-yl]-acetic acid methyl ester, (1h)
{8-[5-(1 ,3-Dioxo-1 ,3-dihydro-isoindol-2-yl)-pentyl]-4-oxo-1 -phenyl-1 ,3,8-triaza- spiro[4.5]dec-3-yl}-acetic acid methyl ester, (1i)
(8-Naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl)-acetic acid methyl ester, (1j) {8-[2-(4-Fluoro-phenoxy)-ethyl]-4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl}- acetic acid methyl ester, (1k)
[8-(6, 7-Dimethoxy-2-oxo-2H-chromen-4-yimethyl)-4-oxo-1 -phenyl-1 ,3, 8-triaza- spiro[4.5]dec-3-yl]-acetic acid methyl ester, (11)
[8-(2-Naphthalen-1-yl-ethyl)-4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester, (1m)
[8-(3-Cyano-benzyl)-4-oxo-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester, (1n)
3-(3-Methoxycarbonylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-8- ylmethyl)-benzoic acid methyl ester, (1o) [8-(4-Bromo-benzyl)-4-oxo-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester, (1p)
[8-(3,4-Dichloro-benzyl)-4-oxo-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester, (1q)
(8-Anthracen-9-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl)-acetic acid methyl ester ,(1r)
5-Guanidino-2-(S)-[2-(8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]dec-3-yl)-acetylamino]pentanoic acid methylester,
N-(2-Guanidino-ethyl)-2-(8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]dec-3-yl)-acetamide, 3-(7-Amino-heptyl)-8-naphthalen-1 -ylmethyl-1 -phenyl-1 ,3,8-triaza- spiro[4.5]decan-4-one,
3-(1 H-lmidazol-4-yl)-2-(S)-[2-(8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3,8- triaza-spiro[4.5]dec-3-yl)-acetylamino]-propionamide,
5-Guanidino-2-(S)-[2-(8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1 ,3, 8-triaza- spiro[4.5]dec-3-yl)-acetylamino]-pentanoic acid amide,
5-Guanidino-2-(R)-[2-(8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]dec-3-yl)-acetylamino]-pentanoic acid amide,
N-(3-Guanidino-propyl)-2-(8-naphthalen-1 -yimethyl-4-oxo-1 -phenyl-1 ,3, 8-triaza- spiro[4.5]dec-3-yl)-acetamide, 3-(5-Amino-pentyl)-8-naphthalen-1 -ylmethyl-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]decan-4-one,
N-(3-Amino-propyl)-2-(8-naphthaien-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]dec-3-yl)-acetamide,
N-(2-Amino-ethyl)-2-(8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]dec-3-yl)-acetamide,
N-[7-(8-Naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl)- heptylj-guanidine,
3-Ethyl-8-naphthalen-1 -ylmethyl-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]decan-4-one,
2-(8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl)-N- (tetrahydro-furan-2-ylmethyl)acetamide,
2-(8-Naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl)-N-[3-
(2-oxo-pyrrolidin-1-yl)-propyl]-acetamide,
6-Amino-2-(S)-[2-(8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-thaza- spiro[4.5]dec-3-yl)-acetylamino]-hexanoic acid amide,
N-Carbamoylmethyl-2-(8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]dec-3-yl)-acetamide,
2-(S)-[2-(8-Naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl)- acetylamino]-phenyl-acetamide, 6-Amino-2-(S)-(2-{6-amino-2-(S)-[2-(8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-
1 ,3,8-triaza-spiro[4.5]dec-3-yl)-acetylamino]-hexanoylamino}-acetylamino)- hexanoic acid amide,
5-Guanidino-2-(S)-{2-[2-(8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]dec-3-yl)-acetylamino]-acetylamino}-pentanoic acid amide or 5-Guanidino-2-(S)-(2-{2-[2-(8-naphthalen-1-ylmethyl-4-oxo-1-phenyl-1 ,3,8-triaza- spiro[4.5]dec-3-yl)-acetylamino]-acetylamino}-acetylamino)-pentanoic acid amide.
In a most preferred embodiment of the the invention the compounds are selected from the following:
(4-Oxo-8-phenethyl-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl)-acetic acid methyl ester,
[8-(2-Naphthalen-1-yl-ethyl)-4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester, [8-(4-Bromo-benzyl)-4-oxo-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester,
[8-(3,4-Dichloro-benzyl)-4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester,
5-Guanidino-2-(S)-[2-(8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]dec-3-yl)-acetylamino]-pentanoic acid amide,
5-Guanidino-2-(R)-[2-(8-naphthalen-1-yimethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]dec-3-yl)-acetylamino]-pentanoic acid amide or
3-(7-Amino-heptyl)-8-naphthalen-1 -ylmethyl-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]decan-4-one.
In a third aspect the invention comprises use of a compound of the general formula
wherein
R1 is phenyl, arylalkyl or thienyl, optionally substituted with one or more of halo- gen, cyano, nitro, trifluoromethyl, C1 6-alkyl, hydroxy, C^-alkoxy or NR6R8 wherein R6 and R8 independently are hydrogen or C^-alkyl, or R1 is C,.6-alkyl; R2 is phenyl, phenoxy, benzodioxinyl, cyanodiphenylmethyl, aminophenyl, C^- monoalkylaminophenyl,
naphthyl, tetrahydronaphthyl, anthryl, furanyl, indanyl, indolyl, isoindolyl, benzothienyl, benzofuranyl, coumari- nyl, said groups may be substituted with one or more of halogen, cyano, nitro, trifluoromethyl, C^-alkyl, hydroxy, C.,.6-alkoxy, C(0)R7, wherein R7 is -OH, C^- alkoxy or -NR12R13, wherein R12 and R13 independently are hydrogen or C _6 alkyl;
R3 is hydrogen, C.,_6-alkyl, phenyl, benzyl or acetyl;
R4 is hydrogen or (CH2)m-(CHR9)-(CH2)p-AR11, wherein m and p independently are 0-4 and R9 is hydrogen, C1-6-alkyl, phenyl or arylalkyl, R11 is C^-alkyl, hydroxy, C g-alkoxy, guanidino, an amino acid residue or a 2-4 peptidyl residue with a C- terminal group consisting of either OCH3, or NH2 ; R11 can also be a group NR1 R15 wherein R14 and R15 independently are hydrogen, C^ alkyl, (CH2)qR )116
where q can be 0 to 6 and R16 can be a C3-C7 membered cycloalkyl ring, an optionally substituted aromatic or heteroaromatic ring, an aliphatic ring containing one or more heteroatoms, an alkoxy or aryloxy group, an amino or a guanidino group; A is -CH2 or -C=0; provided that when R11 is an amino acid or peptidyl residue, then A is a -C=0 group; or
R5 is hydrogen or C^-alkyl;
z is CHR10 wherein R10 is hydrogen, C^-alkyl, phenyl or arylalkyl - or z is C2.8- alkylene, C2.8-alkenylene or C2.8-alkynylene;
n is 1 or 2 or a pharmaceutically acceptable salt thereof for the treatment of migraine, non insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation, incontinence and/or vasomotor disturbances, in particular the peripheral vasomotor effects known as hot flushes or hot flashes.
In another embodiment of the invention the composition is in a form suitable for oral, nasal, transdermal, pulmonal, or parenteral administration.
In a further embodiment of the present invention the compound of the formula la or lb is administered as a dose in the range from about 0.01 to about 5000 mg per patient per day, preferably from about 1 to about 1000 mg per patient per day, especially from about 10 to about 100 mg per patient per day, e.g. about 100 mg per patient per day.
In a fourth aspect the invention relates to a method for the treatment or prevention of migraine, Type II diabetes, sepsis, inflammation, incontinence and/or vasomotor disturbances, in particular the peripheral vasomotor effects
known as hot flushes or hot flashes, the method comprising administering to a patient in need thereof an effective amount of compound of the formula la or lb or a pharmaceutically acceptable salt thereof.
In a fifth aspect the invention relates to a pharmaceutical composition comprising triaza-spiro compounds with high affinity to the nociceptin receptor, or a pharmaceutically acceptable salt thereof.
In a sixth aspect the invention relates to a method of treatment symptoms of drug withdrawal, in particular abstinence symptoms occurring during withdrawal from abusive drugs.
The effective, such as the therapeutically effective amount of a compound of the formula la or lb will depend upon the mode of administration, on the therapy desired, form in which administered, the subject to be treated and the body weight of the subject to be treated, and the preference and experience of the physician or veterinarian in charge.
As used herein the term "patient" comprises any mammal which may benefit from treatment or prevention of vasomotor disturbances, such as a human, especially if the mammal is a female, such as a woman. However, "patient" is not intended to be limited to a woman.
As used herein the term " small organic compounds" refers to compounds with a molecular weight below 1000 and with less than 5 amide bonds or no amide bonds.
As used herein the term "triaza-spiro" represents a compound of formula
with various substituents as defined above.
As used herein the term "high affinity" represents an IC50 below 1 μM.
As used herein the term "arylalkyl" refers to a straight or branched saturated carbon chain containing from 1 to 6 carbons substituted with an aromatic hydrocarbon; such as benzyl, phenethyl, 3-phenylpropyl, 1-naphtylmethyl, 2-(1- naphtyl)ethyl and the like.
As used herein the term
represent a branched or straight alkyl group or cycloalkyl with five or six carbon in the ring. Typical C^-alky! groups include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, butyl, iso- butyl, sec-butyl, tert-butyl, pentyl, iso-pentyl, hexyl, iso-hexyl and the like.
As used herein the term "CLg-alkoxy" alone or in combination is intended to include those groups of the designated length in either a linear or branched or cyclic configuration linked thorugh an ether oxygen having its free valence bond from the ether oxygen. Examples of linear alkoxy groups are methoxy, ethoxy, propoxy, butoxy, pentoxy and hexoxy. Examples of branched alkoxy are isopropoxy, sec-butoxy, tert-butoxy, isopentoxy and isohexoxy. Example of cyclic alkoxy are cyclopropyloxy, cyclobutyloxy, cyclopentyloxy and cyclohexyloxy.
As used herein the term "halogen" means fluorine, chlorine, bromine or iodine.
As used herein the term "amino acid residue or peptidyl residues" is also meant to comprise naturally occurring or synthetically produced amino acids linked to the compound by an amide bond.
As used herein the terms "C2 8.-alkylene" represent a branched or straight alkyl group having from one to the specified number of carbon atoms. Typical C2_8- alkylene groups include, but are not limited to, ethylene, n-propylene, iso- propylene, butylene, iso-butylene, sec-butylene, tert-butylene, pentylene, iso- pentylene, hexylene, iso-hexylene and the like.
As used herein the terms "C2.8.-alkenylene" represents an olefinicaily unsatu- rated branched or straight group with at least one double bond. Examples of such groups include, but are not limited to, vinyl, 1 -propenylene, allylene, iso- propenylene, 1 ,3-butadienylene, 1 -butenylene, hexenylene, pentenylene, and the like.
As used herein the terms "C2.8.-alkynylene" represent an unsaturated branched or straight group having at least one triple bond. Examples of such groups include, but are not limited to, 1 -propynylene, 1 -butynylene, 2-butynylene, 1 - pentynylene, 2-pentynylene and the like.
As used herein the term "ligand" is also meant to comprise a compound with agonistic, partial agonistic or antagonistic activity specifically binding to receptor proteins.
As used herein the term "treatment" is also meant to comprise prophylactic treatment.
The preparation of compounds of formula la may include, but are not limited to the following methods:
A:
(ID (III)
(la)
A compound of formula (II) wherein R1, R3, R R5 and n are as defined above may be allowed to react with a compound of formula (III), wherein R2 and z are defined as above and X is a suitable leaving group such as halogen, p-toluene sulphonate or mesylate. This alkylation reaction may be carried out in a solvent such as acetone, dibutylether, 2-butanone, methyl ethyl ketone, ethyl acetate, tetrahydrofuran (THF) or toluene in the presence of a base e.g. sodium hydride and a catalyst, e.g. an alkali metal iodide at a temperature up to reflux temperature for the solvent used for e.g. 1 to 120 h. Compounds of formula (II) may be prepared by known methods, e.g. as described in US-Patent 3,238,216. Compounds of formula (III) are commercially available or may readily be prepared by methods familiar to those skilled in the art.
B:
(N) (IV) (V)
(la)
A compound of formula (II) wherein R1, R3, R4, R5 , and n are as defined above may be allowed to react with an aldehyde of formula (IV), wherein R2is as defined above and the linker y is one C-atom shorter than linker z, where z is as defined above, to form an imine of formula (V). The reaction may be carried out in a suitable solvent like a lower aliphatic alcohol as e.g. ethanol or an ether as e.g. tetrahydrofuran or a mixture of these. In a second step, the formed iminium derivative of formula (V) is then reduced to an amine of formula (la) by the addition of a suitable reducing agent, e.g. a hydride as sodium cyanoborohydride or sodium borohydride in e.g. 1 to 120 h at 20° C to reflux temperature.
Compounds of formula (la) may also be prepared in a parallel fashion using solid phase technology, e.g. as described by F. Zaragoza and S.V. Petersen, Tetrahedron, 52, 10823 (1996). In this case, R4 in a compound of formula (II) is replaced by (CH2)m-(CHR9)-(CH2)p-C(0)R7b, wherein m, p and R9 are as defined above and R7 is a resin-O- or a resin-NH-residue.
The above described reactions are followed by a cleavage from the resin to form a compound of formula (la). The Cleavage conditions used depend on the type of resin used and are commonly known to those skilled in the art.
C:
(VI) (VII) (la)
A compound of formula (VI) wherein R\ R2, R3, R5 , z and n are as defined above, may be deprotonated at N3 with a suitable base, as sodium hydride, n-butyl lith- ium or potassium tert.-butoxide in an aprotic solvent as e.g. dimethyl formamide or dimethylsulfoxide and subsequently allowed to react with a reagent of formula (VII), wherein R4 and X are as defined above. The reaction may be carried out at temperatures from 0 °C to reflux temperature, preferably at room temperature in 1 to 24 hours, to form a compound of formula (la).
D:
A compound of formula (la) may further be synthesized by allowing a compound of formula (VIII), wherein R1 , R2, R3, R5 , R9 , m, p, n an z are as described above, to react with a compound of formula (IX), in which the R11 group bears a residue which is coupled to a resin and may be subsequently cleaved from the resin as an ester or amide moiety. The coupling reaction between (VIII) and (IX) may be carried out in a suitable solvent as e.g. dimethyl formamide or N-methyl pyrrolidone using e.g. a coupling reagent from the class of the carbodiimides, a benzotriazol and an optional base as a hindered tertiary amine. These amide couplings are well documented in the literature and commonly known. Compounds of formula (IX)
may be commercially available resins, or can be prepared from such commercially available resins using general alkylation, reductive amination, or acylation methods.
Within the present invention, the compound of the formula la or lb may be prepared in the form of pharmaceutically acceptable salts such as base or acid addition salts, especially acid-addition salts, including salts of organic acids and min- eral acids. Examples of such salts include salts of organic acids such as formic acid, fumaric acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, succinic acid, malic acid, maleic acid, tartaric acid, citric acid, benzoic acid, salicylic acid and the like. Suitable inorganic acid-addition salts include salts of hydrochloric, hydrobromic, sulphuric and phosphoric acids and the like. Further examples of pharmaceutically acceptable inorganic or organic acid addition salts include the pharmaceutically acceptable salts listed in Journal of Pharmaceutical Science. 66, 2 (1977) which are known to the skilled artisan.
Also intended as pharmaceutically acceptable acid addition salts are the hydrates which the present compound of the formula la or lb are able to form.
The acid addition salts may be obtained as the direct products of compound synthesis. In the alternative, the free base may be dissolved in a suitable solvent containing the appropriate acid, and the salt isolated by evaporating the solvent or otherwise separating the salt and solvent.
The compounds of the formula la or lb of this invention may form solvates with standard low molecular weight solvents using methods known to a person skilled in the art.
The compound of the formula la or lb may be administered in pharmaceutically acceptable acid addition salt form . Such salt forms are believed to exhibit approximately the same order of activity as the free base forms.
A pharmaceutical composition for use in accordance with the present invention comprises, one or more compound of the formula la or lb as active ingredient(s), or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier or diluent.
Pharmaceutical compositions containing compounds of the formula la or lb of the present invention may be prepared by conventional techniques, e.g. as described in Remington: The Science and Practise of Pharmacy. 19th Ed., 1995. The compositions may appear in conventional forms, for example capsules, tablets, aerosols, solutions, suspensions or topical applications.
Typical compositions include Compound of formula la or lb or a pharmaceutically acceptable acid addition salt thereof, associated with a pharmaceutically acceptable excipient which may be a carrier or a diluent or be diluted by a carrier, or enclosed within a carrier which can be in the form of a capsule, sachet, paper or other container. In making the compositions, conventional techniques for the preparation of pharmaceutical compositions may be used. For example, the active compound will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a ampoule, capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be solid, semi-solid, or liquid material which acts as a vehicle, excipient, or medium for the active compound. The active compound can be adsorbed on a granular solid container for example in a sachet. Some examples of suitable carriers are water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil,
gelatine, lactose, terra alba, sucrose, cyclodextrin, amylose, magnesium stearate, talc, gelatine, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethylcellulose and polyvinylpyrrolidone. Similarly, the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax. The formulations may also include wetting agents, emulsifying and suspending agents, preserving agents, sweetening agents or flavouring agents. The formulations of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the patient by employing procedures well known in the art.
The pharmaceutical compositions can be sterilized and mixed, if desired, with auxiliary agents, emulsifiers, salt for influencing osmotic pressure, buffers and/or colouring substances and the like, which do not deleteriously react with the active compounds.
The route of administration may be any route, which effectively transports the active compound to the appropriate or desired site of action, such as oral, nasal, pulmonary, transdermai or parenteral e.g. rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment.
If a solid carrier is used for oral administration, the preparation may be tabletted, placed in a hard gelatine capsule in powder or pellet form or it can be in the form of a troche or lozenge. If a liquid carrier is used, the preparation may be in the form of a syrup, emulsion, soft gelatine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution.
For nasal administration, the preparation may contain a compound of formula la or lb dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application. The carrier may contain additives such as solubilizing agents, e.g. propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin, or preservatives such as parabenes.
For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, corn starch, and/or po- tato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed.
A typical tablet which may be prepared by conventional tabletting techniques may contain:
Core:
Active compound (as free compound or salt thereof) 100 mg Colloidal silicon dioxide (Aerosil) 1.5 mg Cellulose, microcryst. (Avicel) 70 mg Modified cellulose gum (Ac-Di-Sol) 7.5 mg Magnesium stearate Ad.
Coating: HPMC approx. 9 mg *Mywacett 9-40 T approx. 0.9 mg
*Acylated monoglyceride used as plasticizer for film coating.
Any novel feature or combination of features described herein is considered essential to this invention.
Pharmacological effects:
Male Sprague Dawley rats ( 300±25 g) were anaesthetized with pentobarbital sodium (50 mg/kg i.p.) and polyethylene catheters were positioned in both femoral veins for the intravenous administration of drugs, such as nociceptin and analogues, and into the left femoral artery in order to measure arterial blood pressure and heart rate. The trachea was cannulated with polyethylene tubing and the rat was pithed, ventilated and drug treated as described by Nuki Y. et al. (Effects of Dorsal Rhizotomy on Depressor Response to Spinal Cord Stimulation Mediated by Endogenous Calcitonin Gene-related Peptide in the Pithed Rat. J. Neurosurg. 1993; 79:899-904).
Examples:
The process for preparing compounds of formula la or lb and preparations containing them is further illustrated in the following examples, which, however, are not to be construed as limiting.
Hereinafter, TLC is thin layer chromatography, CDCI3 is deuterio chloroform and DMSO-dg is hexadeuterio dimethylsulfoxide. The structures of the compounds are confirmed by either elemental analysis or NMR, where peaks assigned to characteristic protons in the title compounds are presented where appropriate. 1H NMR shifts (δH) are given in parts per million (ppm).
HPLC-MS analyses were performed on a PE Sciex API 100 LC/MS System using Method 1 : a WatersTM 3 mm x 150 mm 3.5 μ C-18 Symmetry column and positive ionspray with a flow rate of 20 μL/minute. The column was eluted with a
linear gradient of 5-90% A, 85-0% B and 10% C in 15 minutes at a flow rate of 1 ml/min (solvent A = acetonitrile, solvent B = water and solvent C = 0.1% trifluoroacetic acid in water).
Method 2: a YMC ODS-A 120 A s - 5μ 3 mm x 50 mm column and positive ionspray with a flow rate of 20 μL/minute. The column was eluted with a linear gradient of 5-90% A, 85-0% B and 10% C in 7.5 minutes at a flow rate of 1.5 ml/min. (solvent A = acetonitrile, solvent B = water and solvent C = 0.5% trifluoroacetic acid in water).
M.p. is melting point and is given in °C and is not corrected. Column chromatography was carried out using the technique described by W.C. Still et al,
J. Org. Chem. (1978), 43, 2923-2925 on Merck silica gel 60 (Art. 9385).
Compounds used as starting materials are either known compounds or compounds which can readily be prepared by methods known per se.
EXAMPLE 1
8-Alkylated 4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl)-acetic acid methyl esters (Method A)
Wang resin (2.17 g, 2.0 mmol) was placed in a solid synthesis flask equipped with a glass frit and swelled in dry dimethylformamide (15 ml) for 15 minutes. The excess solvent was removed by suction and a solution of Fmoc-3-carboxymethyl-1- phenyl-1 , 3, 8-triazaspiro[4.5]decan-4-one (2.05 g, 4.0 mmol) in dimethylformamide (8.0 ml) was added. The mixture was agitated for 5 minutes, dry pyridine (0.53 ml)
and 2,6-dichlorobenzoyl chloride (0.54 ml, 4.0 mmol) was added and the mixture was agitated for 20 h. The solution was removed by suction and the resin was washed with dimethylformamide (2x 10 ml) and 1 ,2-dichloroethane (4x 10 ml). Dichloromethane (8 ml), pyridine (0.81 ml, 10 mmol) and benzoyl chloride (0.81 ml, 7.0 mmol) were added to the resin and the mixture was agitated for 2 h. The solution was removed by suction and the resin was washed with dichloroethane (4x 10 ml), methanol (2x 10 ml) and N,N-dimethylformamide (2x 10 ml). To remove the Fmoc group, the resin was agitated with 20% piperidine in N,N- dimethylformamide (10 ml) for 30 minutes. The solution was removed by suction, the resin was washed with N,N-dimethylformamide (2x 10 ml), dichloromethane (4x 10 ml) and methanol (3x 10 ml) and dried. This yielded the Wang resin (2.53 g) with attached 3-carboxy-1-phenyl-1 ,3,8-triazaspiro[4.5]decan-4-one (0.67 mmol/g).
The following solid phase syntheses were carried out parallely using the apparatus described by F. Zaragoza and S.V. Petersen, Tetrahedron, 52, 10823 (1996). Equal portions of the above resin (67 mg, 0.045 mmol) were placed in Teflon tubes equipped with a frit on a mechanical shaker. Dimethyl sulfoxide (1 ml), the appropriate alkyl bromide R2-z-x (0.225 mmol) and diisopropylethylamine (0.029 g, 0.225 mmol) were added to the resin. The tubes were heated to 60 °C and agitated for 16 h. The resin was drained, washed with dimethyl sulfoxide (2x 1 ml), dichloromethane (4x 1 ml) and methanol (2x 1 ml). A solution of sodium methoxide (0.009 mmol) in a mixture of tetrahydrofu- ran/methanol 4:1 (2 ml) was added to the resin and the suspension was agitated at 50 °C for 16 h. The mixture was neutralized by addition of a solution of acetic acid (0.01 mmol) in a mixture of tetrahydrofuran/methanol 4:1 (1 ml), the solution was drained and the resin was washed with tetrahydrofuran (1 ml). The combined filtrates were concentrated in vacuo to yield the title compounds.
8-alkylated 4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl)-acetic acid methyl esters (Method B)
Wang resin with attached 3-carboxy-1 -phenyl-1 , 3, 8-triazaspiro[4.5]decan-4-one (0.88 mmol/g), prepared similarly as described in example was used for this li- brary of compounds. Equal portions of the resin (62 mg, 0.055 mmol) were placed in Teflon tubes equipped with a frit on a mechanical shaker. The resin was allowed to swell in 2 ml dry tetrahydrofuran for 0.5 h, the solvent was removed with suction and the respective aldehyde (0.275 mmol), dissolved in 1 ml tetrahydrofuran was added, followed by 50% v/v acetic acid (0.225 ml). The mixture was shaken under nitrogen atmosphere at room temperature for 0.5 h. A solution of sodium cyanoborohydride (1 M in tetrahydrofuran, 0.20 ml) was added and the mixture was shaken at room temperature for 16 h. The resin was drained, washed with tetrahydrofuran (2x 1 ml), water (2x 1 ml), tetrahydrofuran (2x 1 ml), dichloromethane (2x 1 ml) and tetrahydrofuran/methanol 4:1 (2x 1 ml). A solution of sodium methoxide (0.009 mmol) in a mixture of tetrahydrofuran/methanol 4:1 (2 ml) was added to the resin and the suspension was agitated at 50 °C for 16 h. The mixture was neutralized by addition of a solution of acetic acid (0.01 mmol) in a mixture of tetrahydrofuran/methanol 4:1 (1 mi), the solution was drained and the resin was washed with tetrahydrofuran (1 ml). The combined filtrates were concentrated in vacuo to yield the title compounds.
EXAMPLE 3 2-(8-naphthalen-1-ylmethyl-4-oxo-1-phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl)- propionic acid ethyl ester hydrochloride
Sodium hydride, 60% (0.156 g, 3.9 mmol) was suspended in dry heptane (5 ml) and stirred under nitrogen for 5 minutes. The solvent was decanted and dry dimethyl formamide (2 ml) was added. 8-Naphthalen-1-ylmethyl-1-phenyl-1 ,3,8- 0 triazaspiro[4.5]decan-4-one (1.115 g, 3.0 mmol), dissolved in dry dimethyl formamide (11 ml) was added dropwise under cooling in an ice bath. The mixture was stirred at 0 °C for 1 h. An aliquot of the resulting solution of deprotonated 1- phenyl-8-naphthalen-1-ylmethyl-1 ,3,8-triazaspiro[4.5]decan-4-one (2.3 ml, 0.5 mmol) was added to ethyl 2-bromopropionate and the mixture was stirred at room 5 temperature overnight. Water (15 ml) and ethyl acetate (15 ml) were added and the mixture was shaken, the organic phase was separated and successively washed with water (2 x 10 ml) and brine (10 ml). The organic phase was dried over magnesium sulfate and the solvent was evaporated in vacuo. The crude product was purified by column chromatography on silica gel using a mixture of
ethyl acetate and dichloromethane 1 :4 to give the pure base, which was dissolved in tetrahydrofuran (3 ml) and an excess of a solution of hydrogen chloride in ether was added. Crystallization occured on the careful addition of ether (6 ml). The precipitate was collected by filtration and dried to give the title compound (217 mg, 85% yield).
M.p. 175 - 181 °C.
Calculated for
HCI: C, 68.56%; H, 6.75%; N, 8.27%; Found : C, 68.36%; H, 7.03%; N, 7.93%.
Following the same preparation method, the following compounds were prepared:
3-Methyl-2-(8-naphthalen-1-ylmethyl-4-oxo-1-phenyl-1.3.8-thaza-spiro[4.51dec-3-yl')- butyric acid ethylester hydrochloride
LC/MS (Method 2): m/e = 500.2 (MH+); RT = 6.60 min.
Calculated for C31H37N3θ3 HCI, 0.25 H20: C, 69.45%; H, 7.14%; N, 7.84%; Found : C, 68.87%; H, 7.18%; N, 7.77%.
2-(8-Naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1.3.8-triaza-spiro[4.5]dec-3-yl)- hexanoic acid ethyl ester hydrochloride
M.p. 169 - 177 °C
Calculated for C32H39N303 HCI, 0.75 H20: C, 68.19%; H, 7.42%; N, 7.45%; Found : C, 67.92%; H, 7.47%; N, 7.34%.
5-(8-Naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1.3.8-triaza-spiro[4.51dec-3-yl.- pentanoic acid ethyl ester hydrochloride
LC/MS (Method 2): m/e = 500.2 (MH+); RT = 6.08 min.
Calculated for C31H37N303 HCI, 1.25 H20: C, 66.12%; H, 7.34%; N, 7.46%; Found : C, 66.23%; H, 7.13%; N, 7.34%.
4-( 8-Naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1.3.8-triaza-spiro[4.5ldec-3-yl .-butyric acid ethyl ester hydrochloride
M.p. 200 - 203 °C
Calculated for C30H35N3O3 HCI, 0.3 tetrahydrofuran: C, 68.92%; H, 7.12%; N, 7.73%; Found : C, 68.63%; H, 7.08%; N, 7.64%.
EXAMPLE 4 8-Naphthalen-1 -ylmethyl-1 -phenyl-1 ,3,8-triaza-spiro[4.5]decan-4-one
1 -Phenyl-1, 3, 8-triaza-spiro[4.5]decan-4-one (185.04 g, 0.76 mol) was suspended in 2-butanone (3600 ml). 1-(Chloromethyl)naphthalene (169.21 g, 0.91 mol), dry potassium carbonate (345.42 g, 2.50 mol) and sodium iodide (113.91 g, 0.76 mol) were added and the mixture was heated at reflux temperature for 24 h. The solvent was evaporated in vacuo and the remainder was distributed between water (2000 mi) and diethyl ether (2000 ml). The formed precipitate was collected by filtration, washed successively with water (800 ml), toluene (600 ml) and
icecold acetone (2 X 200 ml) and dried affording the title compound as a powder (191.20 g, 68% yield).
M.p. 207 -215 °C Calculated for C24H25N30 :
C, 77.60%; H, 6.78%; N, 11.31%; Found : C, 77.23%; H, 6.90%; N, 11.29%.
EXAMPLE 5
(8-Naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1.3.8-triaza-spiro[4.5]dec-3-yl. -acetic acid methyl ester
Sodium hydride (60%, 12.96 g, 0.324 mol) was stirred with dry n-heptane under nitrogen and the solvent was decanted from the settled hydride. Icecold dimethyl formamide (600 ml) was added and the resulting solution was added during 0.5 h to a stirred solution of 8-naphthalen-1 -ylmethyl-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]decan-4-one (prepared as described in example 4) in dimethyl formamide (900 ml) at 0 - 5 °C. After stirring for additional 0.5 h, a solution of methyl bromoacetate (54.84 g, 0.348 mol) in dimethylformamide (20 ml) was added under ice cooling. The reaction mixture was allowed to warm up to room temperature while stirring for additional 1 h and was then poured into a mixture of ethyl acetate (800 ml) and ice water (1900 ml) under vigorous stirring. The organic phase was separated and the aqueous phase was extracted with ethyl acetate (2 X 400 ml). The combined organic phases were successively washed
with water (2 X 300 ml) and brine (2 X 250 mi) and dried over magnesium suifate. The solution was concentrated in vacuo. ethyl acetate ( 30 ml) was added to the warm residue under stirring and crystallisation was completed by cooling to room temperature. The product was filtered, washed on the filter with icecold ethyl acetate and dried, to afford the title compound (111.06 g, 83% yield) as a powder.
M.p. 122 - 135 °C Calculated for C27H29N303 : C, 73.11%; H, 6.59%; N, 9.47%; Found : C, 72.84%; H, 6.71 %; N, 9.36%.
EXAMPLE 6 (8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1.3.8-triaza-spiro[4.5]dec-3-yl)-acetic acid
(8-Naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl)-acetic acid methyl ester (44.40 g, 0.1 mol, prepared as described above) was dissolved in a mixture of 2 N sodium hydroxide (165 ml, 0.33 mol) and ethanol (500 ml) and stirred at room temperature for 16 h. Dichloromethane (700 ml) was added and pH was adjusted to 5 by the addition of 6 N hydrochloric acid. The organic phase was separated, washed with water (2 x 200 ml and concentrated to 300 ml in vacuo. Water (300 ml) and dichloromethane (100 ml) were added and the slurry was stirred overnight. The product was collected by filtration, washed successively with water (4 x 100 ml, dichloromethane (2 x 50 ml) and acetone (2 x 50 ml) and dried, affording the title compound as a powder (44.6 g, 97% yield).
1 H NMR (200 MHz, DMSO-d6) δ 1 .62 (d, 2H), 2.56 (q, 2H), 2.88 (m, 4H), 4.03 (s, 2H), 4.07 (s, 2H), 4.68 (s, 2H), 6.78 (t, 1 H), 6.84 (d, 2H), 7.23 (d, 2H), 7.40 - 7.70 (m, 4H), 7.90 (dd, 2H), 8.42 (d, 1 H).
Calculated for C26H27N303 , 1.25 H20: C, 69.08%; H, 6.58%; N, 9.30%; Found : C, 68.89%; H, 6.39%; N, 9.13%.
EXAMPLE 7
(8-Naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1.3.8-triaza-spiro[4.5]dec-3- yl.acetylglycine methyl ester
Wang resin loaded with Fmoc-glycine (88 mg, 0.045 mmol) was placed in a
Teflon tube equipped with a frit on a mechanical shaker. The resin was allowed to swell in dimethyl formamide (1.5 ml) for 1 h. The solvent was removed by suction and the resin was agitated with 20% pipehdine in N,N-dimethylformamide (1.5 ml) for 30 minutes. The solution was removed by suction and the resin was washed with N,N-dimethylformamide (3x 1.5 ml). To a solution of (8-naphthalen-1- ylmethyl-4-oxo-1-phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl)-acetic acid (0.0773 g, 0.18 mmol) in dimethyl formamide (1.6 ml), diisopropyicarbodiimide_(29 μl, 0.18 mmol) and 1-hydroxy-1 H-benzotriazol (0.0243 g, 0.18 mmol) were added and the mixture was stirred at room temperature for 0.5 h. The resulting solution and diisopropylethylamine (31 μl, 0.18 mmol) were added to the above resin and this was shaken at room temperature overnight. The resin was filtered and washed
with dimethylformamide (2 x 1.5 ml), dichloromethane (4 x 1.5 ml), methanol (2 x 1.5 ml) and tetrahydrofuran/methanol 4:1 (2 x 1.5 ml). A solution of sodium methoxide (0.009 mmol) in a mixture of tetrahydrofuran/methanol 4:1 (2 ml) was added to the resin and the suspension was agitated at 50 °C for 16 h. The mixture was neutralized by addition of a solution of acetic acid (0.01 mmol) in a mixture of tetrahydrofuran/methanol 4:1 (1 ml), the solution was drained and the resin was washed with tetrahydrofuran (1 ml). The combined filtrates were concentrated in vacuo to afford the title compound.
The following compounds were parallel synthesized using the above described method:
EXAMPLE 8
5-Guanidino-.S.-2-[2-.8-naphthalen-1-ylmethyl-7-oxo-1.3.8-triaza-spiro[4.5]dec-3- 5 yl)-acetylamino]-pentanoic acid amide, ditrifluoroacetate
One equivalent (1.0 g, 0.69 mmol) of Rink Amide (AM) resin (0.69 mmol/g, pur- chased from Novabiochem) was suspended in piperidine/N,N-dimethylformamide (20%) (all volumes are calculated as 10 ml/gram of resin) and shaken on a mechanical shaking apparatus for 0.5 h. The resin was filtered, rinsed with N,N- dimethylformamide, suspended in piperidine/N,N-dimethylformamide (20%) and shaken for 0.5 h. The resin was filtered and washed as follows: 3 x N,N- dimethylformamide /water (90%), 2 x ethanol, 3 x N,N-dimethylformamide, 5 x methylene chloride. The resin was dried in vacuo and suspended in N,N- dimethylformamide. Fmoc-Arg(Pbf).OH (1.7 g, 01.7 mmol, 4 equivalents), EDAC (N-(3-dimethylaminopropyl)-N'-ethyl carbodiimide hydrochloride) (0.51 g, 2.68 mmol, 4 equivalents), and HOBT (1-hydroxybenzotriazole) (0.36 g, 2.68 mmol, 4 equivalents) were added and the reaction was allowed to shake for 16 h. The resin was filtered and washed successively with 3 x N,N-dimethylformamide /water (90%), 3 x N,N-dimethylformamide, 3 x methylene chloride, was suspended in piperidine/N,N-dimethylformamide (20%) and shaken for 0.5 h. The resin was filtered and washed as follows: 3 x N,N-dimethylformamide /water (90%), 2 x ethanol, 3 x N,N-dimethylformamide, 5 x methylene chloride. The resin was dried in vacuo and suspended in N,N-dimethylformamide and (8- naphthalen-1-ylmethyl-4-oxo-1-phenyi-1 ,3,8-triaza-spiro[4.5]dec-3-yl)-acetic acid (1.08 g, 2.51 mmol, 3.6 equivalents) was added followed by EDAC (0.47 g, 2.51 mmol, 3.6 equivalents), HOBT (0.33 g, 2.51 mmol, 3.6 equivalents) and the reac- tion was allowed to stir at room temperature for 20 h. The resin was filtered and washed 3 x N,N-dimethylformamide /water (90%), 3 x N,N-dimethylformamide, 3
x methylene chloride and dried in vacuo. The resin was suspended in trifluoroacetic acid/water (95%) and shaken for 2 h. The filtrate was collected and added dropwise to cyclohexane/ether (50%) after which a white precipitate was observed. This white solid was collected and washed 3 x cyclohexane/ether (50%) with the aid of a centrifuge. This was dissolved in a minimum amount of acetonitrile/water (10%) and lyophiiized affording the title compound (273 mg, 50% yield), as a white powder.
HPLC retention time = 11.01 minutes (5 μm C18 4 x 250 mm column, eluting with a 20-80 % gradient of 0.1 % trifluoroacetic acid/acetonitrile and 0.1 % trifluoroacetic acid/water over 30 minutes at 35 °C).
LC/MS (Method 2): m/e = 585.4 ((MH+); RT = 4.43 min.
5-Guanidino-.RV2-[2-.8-naphthalen-1-ylmethyl-7-oxo-1.3.8-triaza-spiro[4.5]dec-3- yl)-acetylamino]-pentanoic acid amide, di-trifluoroacetate
This compound was prepared and purified analogously to EXAMPLE 8 using Rink Amide (AM) Resin (0.69 mmol/g) (0.200 g, 0.138 mmol, 1 equivalent), Fmoc- .D-Arg(Pbf).OH (0.358 g, 0.552 mmol, 4 equivalents) to yield the title compound (73 mg, 59% yield) as a white powder. This powder was assumed to be salted with two equivalents of trifluoroacetic acid.
LC/MS (Method 2): m/e = 585.2 (MH+); RT = 4.42 min.
1H NMR (400 MHz, DMSO-d6) δ 1.4 (bm, 3H), 1.7 (bm, 1 H), 1.8-1.9 (bm, 2H), 2.8
(bm, 2H), 3.1 (m, 2H), 3.4-3.5 (bm, 4H), 3.7 (bm, 1 H), 4.1 (s, 2H), 4.2 (m, 1 H), 4.6 (m, 2H), 4.8-4.9 (bm, 1 H), 6.6-7.4 (bm, 4H), 6.7 (m, 1 H), 6.9 (m, 2H), 7.1 (s, 1 H), 7.2 (t, J= 9 Hz, 2H), 7.4 (s, 1 H), 7.0-7.2 (m, 4H), 7.9 (bs, 1 H), 8.0 (m, 2H), 8.4 (t, J= 9 Hz, 2H), 10.2 (bs, 1 H).
13C NMR (75 MHz, DMSO-d6) δ 24.62, 25.94, 28.61 , 42.37, 48.19, 51.63, 57.22,
63.14, 114.17, 118.02, 123.53, 124.84, 125.77, 126.57, 128.31 , 128.70, 131.64, 132.97, 141.91 , 156.23, 166.06, 172.62, 6 carbons obscured.
5 EXAMPLE 9A
N-Benzyl-2-.8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1.3.8-triaza-spiro[4.5]dec-3- yh-acetamide
10 To a suspension of the the commercially available aminomethylated polystyrene resin (Novabiochem) (20 g, 16 mmol) in dimethylformamide (70 ml) was added a solution of the commercially available BAL-Linker (PerSeptive Biosystems GMBH) (12.88 g, 48.0 mmol) and 1-hydroxybenzotriazole (7.26 g, 48.0 mmol) in 70 ml of dimethylformamide. To this was added N,N'-diisopropylcarbodiimide (6.06 g,
15 48.0 mmol) followed by N,N-diisopropylethylamine (6.19 g, 48.0 mmol). The reaction was allowed to stir 20 h at room temperature. The resin was filtered and washed as follows: 3 x dimethylformamide (50 ml), 3 x tetrahydrofuran (50 ml), 3 x dichloromethane (50 ml), 3 x ether (50 ml). The resin was dried in vacuo and isolated: 23.92 g. IR spectroscopy showed an aldehyde stretching band at 1674
20 cm 1. To a part of this resin (0.200 g, 0.160 mmol) in 1 ,2-dichloroethane (8 ml) at room temperature, was added benzyl amine (0.171 g, 1.60 mmol) followed by sodium triacetoxyborohydride (0.339 g, 1.60 mmol). The reaction was allowed to shake 20 h at room temperature, filtered and washed as follows: 3 x dimethylformamide /water (90/10) (8 ml); 3 x dimethylformamide (8 ml); 3 x di-
chloromethane (8 ml). The resin was suspended in dimethylformamide, treated with (8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl)- acetic acid (0.274 g, 0.640 mmol), 1-hydroxybenzotriazole (0.099 g, 0.640 mmol) and N,N'-diisopropylcarbodiimide (0.081 g, 0.640 mmol). The reaction was al- lowed to shake for 20 h at room temperature. The resin was filtered, suspended in dimethylsulfoxide and heated to 40 °C for 1 h. The resin was again filtered, suspended in dimethylsulfoxide (8 ml) and heated to 40 °C for 1 h. The resin was filtered and washed as follows: 3 x dimethylformamide/water (90/10) (8 ml); 3 x dimethylformamide (8 ml); 3 x dichloromethane (8 ml) and air-dried. The resin was treated with trifluoroacetic acid/water (95/5) (8 ml) for 1 h at room temperature. The filtrate was collected and concentrated in vacuo to give the desired product.
The above example and the following compounds were synthesized in a parallel fashion using the above procedure and the appropriate amine.
EXAMPLE 10A
2-. SV[2-(8-Naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1.3.8-triaza-spiro[4.51dec-3-yn- acetylamino]-5-ureido-pentanoic acid amide
Rink Amide (AM) resin (Novabiochem) (0.200 g, 0.138 mmol) was suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature. The resin was filtered and rinsed with dimethylformamide (8 ml) and again suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for
10 30 min at room temperature; the resin was washed as follows: 3 x dimethylfor- mamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml). The resin was suspended in dimethylformamide (8 ml), Fmoc-L-2-amino- 5-ureido-n-vaieric acid (L-Fmoc-Cit-OH) (0.227 g, 0.552 mmol) and 1- hydroxybenzotriazoie (0.085 g, 0.552 mmol) were added. N,N'-
15 diisopropylcarbodiimide (0.071 g, 0.552 mmol) was added and the reaction was allowed to shake for 20 h at room temperature. The resin was filtered and washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml). The resin was suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room tem-
20 perature. The resin was filtered and rinsed with dimethylformamide (8 ml) and again suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature; the resin was washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml). The resin was suspended in dimethylformamide (8 ml); (8-naphthalen-1-
25 ylmethyl-4-oxo-1-phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl)-acetic acid (0.269 g,
0.552 mmol), 1-hydroxybenzotriazole (0.085 g, 0.552 mmol) and N,N'- diisopropylcarbodiimide (0.071 g, 0.552 mmol) were added. The reaction mixture was allowed to shake at room temperature for 20 h and filtered. The resin was suspended in dimethylsulfoxide (8 ml) and heated to 40 °C for 1 h. The resin was again filtered, suspended in dimethylsulfoxide (8 ml) and heated to 40 °C for an additional 1 h. The resin was filtered and washed as follows: 3 x dimethylforma- mide/water (90/10) (8 ml); 3 x dimethylformamide (8 ml); 3 x dichloromethane (8 ml) and air-dried. The resin was treated with trifluroacetic acid/water (95/5) (8 ml) for 2 h at room temperature. The filtrate was collected and concentrated in vacuo to give the desired product.
The above example and the following examples were synthesized in a parallel manner using the procedure outlined above with the appropriate L-Fmoc- protected amino acid. For examples 10b and 10c, the TFA/water cleavage filtrate was added dropwise into a solution of heptane/ether (50/50) (10 ml) at 0 °C. Compound 10b precipitated and was collected as a white solid. For example 10c, an oily residue was formed, the heptane/ether solution was decanted, the residue was taken up into water/acetonitrile (90/10) (10 ml) and freeze-dried to give a white powder.
EXAMPLE 11A 5-Guanidino-2-.SH2-[2-.8-naDhthalen-1-ylmethyl-4-oxo-1-phenyl-1.3.8-triaza- spiro[4.5]dec-3-ylVacetylamιno]-acetylamino}-pentanoic acid amide
Rink Amide (AM) resin (Novabiochem) (0.200 g, 0.138 mmol) was suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room tem- perature. The resin was filtered and rinsed with dimethylformamide and again suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature; the resin was washed as follows: 3 x dimethylforma- mide/water (90/10) (8 ml), 3 x dimethylformamide(8 ml), 3 x dichloromethane. The resin was suspended in dimethylformamide (8 mL), L-Fmoc-Arg(Pbf)-OH (0.358 g, 0.552 mmol) and 1-hydroxybenzotriazole (0.085 g, 0.552 mmol) were added. N,N'-diisopropylcarbodiimide (0.071 g, 0.552 mmol) was added and the reaction was allowed to shake for 20 h at room temperature. The resin was filtered and washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml). The resin was suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature. The resin was filtered and rinsed with dimethylformamide and again suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature; the resin was washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml). The resin was suspended in dimethylformamide (8 ml), Fmoc.Gly.OH (0.163 g, 0.552 mmol), 1-hydroxybenzotriazole (0.085 g, 0.552 mmol) and N,N'- diisopropylcarbodiimide (0.071 g, 0.552 mmol) were added. The reaction was allowed to shake 20 h at room temperature. The resin was filtered and washed as follows: 3 x dimethylformamide/water (80/20) (8 ml), 3 x dimethylformamide (8
ml), 3 x dichloromethane (8 ml). The resin was suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature. The resin was filtered and rinsed with dimethylformamide and again suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room tem- perature; the resin was washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml). The resin was suspended in dimethylformamide (8 ml); (8-naphthaien-1-ylmethyl-4-oxo-1- phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl)-acetic acid (0.269 g, 0.552 mmol), 1- hydroxybenzotriazole (0.085 g, 0.552 mmol) and N,N'-diisopropylcarbodiimide (0.071 g, 0.552 mmol) were added. The reaction mixture was allowed to shake at room temperature for 20 h and filtered and washed as follows: 3 x dimethylformamide/water (90/10) (8 ml); 3 x dimethylformamide (8 ml); 3 x dichloromethane (8 ml) and air-dried. The resin was treated with trifluoroacetic acid/water (95/5) (8 ml) for 2 h at room temperature. The filtrate was collected and added dropwise to cyclohexane/ether at 0 °C to form a white precipitate.
The above and following examples were prepared according to this procedure using the appropriate amino acids as outlined in the table below.
EXAMPLE 12 5-Guanidino-2-. S 2-{2-[2-( 8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1.3.8-triaza- spiro[4.5]dec-3-yl)-acetylamino]-acetylamino}-acetylamino.-pentanoic acid amide
Rink Amide (AM) resin (Novabiochem) (0.200 g, 0.138 mmol) was suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room tem- perature. The resin was filtered and rinsed with dimethylformamide and again suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature; the resin was washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml). The resin was suspended in dimethylformamide (8 ml), L- Fmoc-Arg(Pbf)- OH (0.358 g, 0.552 mmol) and 1-hydroxybenzotriazole (0.085 g, 0.552 mmol) were added. N,N'-diisopropylcarbodiimide (0.071 g, 0.552 mmol) was added and the reaction was allowed to shake for 20 h at room temperature. The resin was filtered and washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethyGformamide (8 ml), 3 x dichloromethane (8 ml). The resin was sus- pended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature. The resin was filtered and rinsed with dimethylformamide and again suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for
30 min at room temperature; the resin was washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml). The resin was suspended in dimethylformamide (8 ml), Fmoc-Gly-Gly-OH (0.195 g, 0.552 mmol), 1-hydroxybenzotriazole (0.085 g, 0.552 mmol) and N,N'- diisopropylcarbodiimide (0.071 g, 0.552 mmol) were added and the reaction was allowed to shake for 20 h at room temperature. The resin was filtered and washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml). The resin was suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room tem- perature. The resin was filtered and rinsed with dimethylformamide and again suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature; the resin was washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml). The resin was suspended in dimethylformamide (8 ml); (8-naphthalen-1- ylmethyi-4-oxo-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl)-acetic acid (0.269 g, 0.552 mmol), 1-hydroxybenzotriazole (0.085 g, 0.552 mmol) and N,N'- diisopropylcarbodiimide (0.071 g, 0.552 mmol) were added. The reaction mixture was allowed to shake at room temperature for 20 h, filtered and washed as follows: 3 x dimethylformamide/water (90/10) (8 ml); 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml). The resin was treated with trifluoroacetic acid/water (95/5) (8 ml) for 2 h at room temperature. The filtrate was collected and added dropwise to cyclohexane/diethylether (50/50) at 0 °C to form a white precipitate which was collected and washed with the cyclohexane/diethylether solution. 32.5 mg of product were collected.
Calculated MW= 698, LCMS (method 2), retention time= 4.20 min, MH+= 699.
EXAMPLE 13
3-(7-AminoheptylV8-naphthalen-1-ylmethyl-1-phenyl-1.3.8-triaza-spiro[4.5]decan- 4-one. ditrifluoroacetate
Sodium hydride, 60% (0.156 g, 3.9 mmol) was suspended in dry heptane (5 ml) and stirred under nitrogen for 5 minutes. The solvent was decanted and dry dimethyl formamide (4 ml) was added. 8-Naphthalen-1 -ylmethyl-1 -phenyi-1 , 3,8- triazaspiro[4.5]decan-4-one (1.115 g, 3.0 mmol), dissolved in dry dimethyl formamide (11 mi) was added dropwise under cooling in an ice bath. The mixture was stirred at 0 °C for 1 h. The resulting solution of deprotonated 1-phenyl-8- naphthalen-1 -ylmethyl-1 , 3, 8-triazaspiro[4.5]decan-4-one was added dropwise to a stirred solution of 1 ,7-dibromoheptane (3.88 g, 15 mmol) in dimethyl formamide (3 ml) at room temperature and stirring was continued for 1 h. The mixture was then diluted with water (50 ml) and extracted with ethyl acetate (2x 30 ml). The combined organic phases were successively washed with water (2 X 20 ml) and brine (2x 20 ml), dried over MgS04 and evaporated in vacuo. The residue was dissolved in a mixture of tetrahydrofuran (10 ml) and ether (10 ml) and the hydrochloride was precipitated by the dropwise addition of a solution of hydrogen chloride in ether in excess. The precipitate was washed with a 1 :1 mixture of tetrahydrofuran and ether and dried, affording 3-(7-bromo-heptyl)-8-naphthaien-1- ylmethyl-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]decan-4-one (1.192 g, 68% yield) as a powder. LC/MS (Method2): m/e = 550.2 (MH+); RT = 6.74 min.
1 H NMR (200 MHz, CDCI3) d 1.4 (bm, 6H), 1.5-1.9 (m, 6H), 3.3-3.6 (m, 8H), 3.92 (broad dd, 2H), 4.70 (s, 4H), 6.86 (t, 1 H), 7.15 (d, 2H), 7.35 (t, 2H), 7.5-7.7 (m, 3H), 7.92 (dd, 2H), 8.15 (d, 1 H), 8.38 (d, 1 H). The above bromide (0.38 g, 0.65 mmol) was dissolved in a 5 M ammonia solution in ethanol (7.5 ml) and heated in an autoclave at 100 °C for 16 h. The solution was evaporated in vacuo and the residue was purified by preparative HPLC using a C18-silica column. The column was eluted with a linear gradient of 10-90% acetonitril and 90-10% 0.1% trifluoroacetic acid in 15 minutes. The pure fraction was evaporated in vacuo. dissolved in water/acetonitrile and freeze dried, to afford the title compound (0.238 g, 51 % yield) as a powder.
LC/MS (Method2): m/e = 485.4 (MH+); RT = 4.77 min Calculated for C31H40N4O, 2 CF3C02H, 0.5 H20: C, 58.25%; H, 6.00%; N, 7.76%; Found : C, 58.20%; H, 6.13%; N, 7.23%.
The following compounds were synthesized using the above procedure and the appropriate dihaloalkane:
3-.5-Aminopentyl.-8-naphthalen-1 -ylmethyl-1 -phenyl-1.3.8-triaza-spiro[4.5]decan- 4-one. di-trifluoroacetate
LC/MS (Method2): m/e = 457.4 (MH+); RT = 5.17 min Calculated for C29H36N40, 2 CF3C02H:
C, 57.89%; H, 5.59%; N, 8.18%; Found : C, 57.57%; H, 5.54%; N, 8.05%.
3-.9-AminononyB-8-naphthalen-1-ylmethyl-1-phenyl-1.3.8-triaza-spiro[4.5]decan- 5 4-one di-trifluoroacetate
LC/MS (Method2): m/e = 513.6 (MH+); RT = 5.03 min Calculated for C33H44N40, 2.4 CF3C02H: 10 C, 57.73%; H, 5.95%; N, 7.12%; Found : C, 57.75%; H, 6.07%; N, 7.17%.
EXAMPLE 14 3-.3-Dimethylaminopropyl.-8-naphthalen-1 -ylmethyl-1 -phenyl-1.3.8-triaza- 15 spiro[4.5]decan-4-one dihydrochloride
3-(3-chloropropyl)-8-naphthalen-1 -ylmethyl-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]decan- 4-one (0.145 g, 0.30 mmol), prepared using the procedure described in Example 20 13, was added to a 33% solution of dimethylamine in ethanol. Sodium iodide (0.045 g, 0.3 mmol) was added and the mixture was stirred at room temperature
for 24 h. Salts were separated by filtration and the filtrate was evaporated in vacuo. The residue was purified by flash chromatography on silica gel using dichloromethane/ ethyl acetate 1 :1 containing 2.5% triethylamine as the eiuent. The pooled pure fractions were evaporated in vacuo and the residue dissolved in tetrahydrofuran (5 ml) and the hydrochloride was precipitated by the dropwise addition of a solution of hydrogen chloride in ether in excess. The precipitate was collected by filtration and dried, affording the title compound (148 mg, 93% yield) as a powder.
LC/MS (Method2): m/e = 457.4 (MH+); RT = 4.47 min Calculated for C29H36N40, 2 HCI, 2 H20: C, 61.59%; H, 7.48%; N, 9.60%; Found : C, 61.56%; H, 7.23%; N, 9.30%.
The following compound was synthesized using the above procedure.
3-(7-Dimethylaminoheptyl.-8-naphthalen-1 -ylmethyl-1 -phenyl-1.3.8-triaza- spiro[4.5]decan-4-one dihydrochlo de
The compound was synthesized using 3-(7-bromo-heptyl)-8-naphthalen-1- ylmethyl-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]decan-4-one, prepared as described in Example 13.
LC/MS (Method2): m/e = 513.6 (MH+); RT = 4.77 min
1H NMR (400 MHz, CDCI3) d 1.4 (m, 6H), 1.65 (m, 2H), 1.74 (d, 2H), 1.87 (m, 2H), 2.80 (s, 6H), 3.35-3.55 (m, 6H), 3.90 (m, 2H), 4.72 (s, 4H), 6.85 (t, 1 H), 7.13 (d, 2H), 7.35 (t, 2H), 7.55-7.70 (m, 3H), 7.95 (t, 2H), 8.17 (d, 1 H), 8.33 (d, 1 H), 12.4 (broad s, 1 H), 12.7 (broad s, 1 H).
EXAMPLE 15
N-.5-C8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1.3.8.-triazaspiro[4.5|den-3- yl)pentyl.guanidine
3-(5-Aminopentyl)-8-naphthalen-1 -ylmethyl-1 -phenyl-1 ,3,8-triaza-spiro[4.5]decan- 4-one, di-trifluoroacetate (0.137 g, 0.2 mmol) prepared as described in Example 13, was dissolved in dimethylformamide (1 ml) and diisopropylethylamine (0.233 g, 1.8 mmol) and 3,5-dimethylpyrazol-1-carboxamidine nitrate (0.060 g, 0.3 mmol) was added. The mixture was stirred at room temperature for 1 h and the addition of an equal amount 3,5-dimethylpyrazol-1-carboxamidine nitrate was repeated. After stirring for 16 h the mixture was diluted with water (10 ml) and extracted with ether (5x 10 ml). The aqueous phase and undissolved syrup were extracted with dichloromethane (10 ml), the dichloromethane solution was washed with water (5x 10 ml), dried over MgS04 and concentrated in vacuo. affording the title compound (0.047 g, 5.2%) as an amorphous powder.
LC/MS (Method2): m/e = 499.2 (MH+); RT = 4.70 min
1H NMR (400 MHz, DMSO-d6) d 1.3 (m, 2H), 1.45-1.65 (m, 7H), 2.48 (m, 1 H), 2.32 (m, 4H), 3.09 (t, 2H), 3.35 (t, 2H), 3.95 (s, 2H), 4.68 (s, 2H), 6.79 (t, 1 H), 6.88 (d, 2H), 7.23 (t, 2H), 7.50 (d, 2H), 7.59 (dt, 2H), 7.88 (dd, 1 H), 7.95 (d, 1 H), 8.40 (d, 1H).
The following compound was synthesized using the above procedure:
N-.δ-fδ-Naphthalen-l-ylmethyl^-oxo-l-phenyl-I .S.δ.-triazaspiro^.δldec-S- y heptyhguanidine
LC/MS (Method2): m/e = 527.2 (MH+); RT = 4.90 min
1H NMR (200 MHz, DMSO-d6) d 1.2-1.4 (m, 6H), 1.45-1.70 (m, 6H), 2.5-2.9 (m, 6H), 3.15 (m, 2H), 3.35 (t, 2H), 3.95 (s, 2H), 4.62 (s, 2H), 6.80 (m, 3H), 7.23 (t, 2H), 7.30-7.7 (m, 5H), 7.75 (m, 2H), 8.40 (d, 1 H).
EXAMPLE 16 N-.2-Aminoethyπ-2-.8-naphthalen-1-ylmethyl-4-oxo-1-phenyl-1.3.8- triazaspiro[4.5]dec-3-yl.acetamide dihydrochloride
The p-nitrophenylcarbonate derivative of Wang resin was treated with 1 ,2- diaminoethane according to the procedure described in Tetrahedron Letters, 1995, 36, p. 8677. The resulting resin (2.87 g, 2.5 mmol) was placed in a solid synthesis flask equipped with a glass frit and swelled in dry dimethylformamide (50 ml) for 30 minutes and the excess solvent was removed by suction.
To a suspension of (8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]dec-3-yl)-acetic acid (4.88 g, 10 mmol) in dimethyl formamide (30 ml) in a separate flask was added 1-hydroxybenzotriazol (1.35 g, 10 mmol) and diisopropylcarbodiimide (1.26 g, 10 mmol). The mixture was stirred at room tempera- ture for 1 h and then added to the above resin. Diisopropylamine (1.29 g, 10 mmol) was added and the mixture was agitated on a shaker for 16 h. . The solution was removed by suction and the resin was washed with dimethylformamide (2x 50 ml), dimethylsulfoxide (2x 50 ml), dichloromethane (4x 50 ml), methanol (3x 50 ml) and dichloromethane (1x 50 ml). A 1 :1 mixture of di- chloromethane/trifluoroacetic acid (25 ml) was added and the resin was agitated for 30 min. The solution was drained and the resin was washed with dichloromethane (2x 25 ml). The combined filtrates were concentrated in vacuo and the residue was shaken with dichloromethane (50 ml) and saturated NaHC03- solution (25 ml). The organic phase was washed with water (20 ml) and brine (20 ml) and concentrated in vacuo. The residue was dissolved in tetrahydrofuran and a solution of hydrogen chloride in ether was added. The formed precipitate was collected by filtration and dried to afford the title compound (0.67 g, 49%) as a powder.
LC/MS (Method2): m/e = 472.2 (MH+); RT = 4.27 min Calculated for C28H33N502, 2 HCI, 3 H20: C, 56.19%; H, 6.90%; N, 11.70%; Found : C, 56.03%; H, 6.45%; N, 11.34%.
The following compound was synthesized using the above procedure:
N-(3-AminopropylV2-(8-naphthalen-1-ylmethyl-4-oxo-1-phenyl-1.3.8- triazaspiro[4.5]dec-3-yl.acetamide dihydrochloride
The 1 ,3-diaminopropyl Wang resin was prepared using the procedure described above.
LC/MS (Method2): m/e = 486.4 (MH+); RT = 4.27 min Calculated for C29H35N502, 2 HCI, 2.75 H20: C, 57.28%; H, 7.64%; N, 11.52%; Found : C, 57.16%; H, 7.72%; N, 11.20%.
EXAMPLE 17
N-(2-Guanidinoethyl.-2-(8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1.3.8 - triazaspiro[4.5]dec-3-yl.acetamide hydrochloride
To a solution of N-(2-aminoethyl)-2-(8-naphthalen-1-ylmethyl-4-oxo-1-phenyl- 1 ,3,8-triazaspiro[4.5]dec-3-yl)acetamide dihydrochloride (0.203 g, 0.40 mmol) in dimethylformamide (1.5 ml) was added diisopropylethylamine (0.046 g, 3.6 mmol) and 1-H-pyrazole-1-carboxamidine hydrochloride (0.088 g, 0.60 mmol). The mixture was stirred at room temperature for 1 h and the same amount of 1-H-
pyrazole-1-carboxamidine hydrochloride was added. The reaction was stirred for further 48 h, water (10 ml) was added and the solution was washed with ether (5x 10 ml). The aqueous phase was adjusted to pH 1 with diluted hydrochloric acid, washed with dichloromethane (20 ml), adjusted to pH 8 with diluted sodium hy- 5 droxide solution and extracted with dichloromethane (3x 5 ml). The organic phase was concentrated to 5 ml and left for crystallization in a refrigerator. The precipitate was filtered and dried, affording the title compound (135 mg, 66%) as a powder.
10 LC/MS (Method2): m/e = 514.4 (MH+); RT = 4.37 min Calculated for C29H35N702, HCI, 0.7 H20: C, 61.90%; H, 6.70%; N, 17.42%; Found : C, 61.95%; H, 6.52%; N, 17.30%.
15 EXAMPLE 18
6-Amino-2-rS.-.2-(S.-{6-amino-2-[2-.8-naphthalen-1-ylmethyl-4-oxo-1-phenyl- 1.3.8-triaza-spiro[4.5]dec-3-yl.-acetylamino]-hexanoylamino}-acetylamino)- hexanoic acid amide
20
Rink Amide (AM) resin (Novabiochem) (0.200 g, 0.138 mmol) was suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature. The resin was filtered and rinsed with dimethylformamide (8 ml) and again suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 25 30 min at room temperature; the resin was washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane
(8 ml). The resin was suspended in dimethylformamide (8 ml), L Fmoc-Lys(Boc)- OH (0.258 g, 0.552 mmol), 1-hydroxybenzotriazole (0.085 g, 0.552 mmol) and N,N'-diisopropylcarbodiimide (0.071 g, 0.552 mmol) were added and the reaction was allowed to shake for 20 h at room temperature. The resin was filtered and
5 washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml). The resin was suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature. The resin was filtered and rinsed with dimethylformamide (8 ml) and again suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for
10 30 min at room temperature; the resin was washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml). The resin was suspended in dimethylformamide (8 ml); Fmoc-Gly-OH (0.163 g, 0.552 mmol), 1-hydroxybenzotriazole (0.085 g, 0.552 mmol) and N,N'- diisopropylcarbodiimide (0.071 g, 0.552 mmol) were added and the reaction was
15 allowed to shake for 20 h at room temperature. The resin was filtered and washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml). The resin was suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature. The resin was filtered and rinsed with dimethylformamide and again
20 suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature; the resin was washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml). The resin was suspended in dimethylformamide (8 ml); L-Fmoc-Lys(Boc)- OH (0.258 g, 0.552 mmol), 1-hydroxybenzotriazole (0.085 g, 0.552 mmol) and
25 N,N'-diisopropylcarbodiimide (0.071 g, 0.552 mmol) were added and the reaction was allowed to shake for 20 h at room temperature. The resin was filtered and washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml). The resin was suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room tem-
30 perature. The resin was filtered and rinsed with dimethylformamide (8 ml) and
again suspended in dimethylformamide/piperidine (80/20) (8 ml) and shaken for 30 min at room temperature; the resin was washed as follows: 3 x dimethylformamide/water (90/10) (8 ml), 3 x dimethylformamide (8 ml), 3 x dichloromethane (8 ml). The resin was suspended in dimethylformamide (8 ml); (8-naphthalen-1- ylmethyl-4-oxo-1-phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl)-acetic acid (0.269 g, 0.552 mmol), 1-hydroxybenzotriazole (0.085 g, 0.552 mmol) and N,N'- diisopropylcarbodiim.de (0.071 g, 0.552 mmol) were added. The reaction mixture was allowed to shake at room temperature for 20 h, filtered and washed as follows: 3 x dimethylformamide/water (90/10) (8 ml); 3 x dimethylformamide; 3 x di- chloromethane (8 ml). The resin was treated with trifluoroacetic acid/water (95/5) (8 ml) for 2 h at room temperature. The filtrate was collected and added dropwise to heptane/diethylether at 0 °C to form a white precipitate which was collected and washed with the heptane/diethylether solution. 13.7 mg of product were isolated.
Calculated MW= 741 , LCMS (method 2) shows retention time= 3.80 min, MH+= 742.
Claims
1. Use of a small organic compound acting as an opioid receptor ligand for the preparation of a pharmaceutical composition for the treatment of a disease selected from migraine, non insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation, incontinence, vasomotor disturbances, in particular the peripheral vasomotor effects known as hot flushes or hot flashes and/or for alleviating symptoms of drug withdrawal, in particular abstinence symptoms occurring during withdrawal from abusive drugs.
2. Use of a small organic compound according to claim 1 acting as a Nociceptin receptor ligand with a molecular weight of less than 1000 or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
3. Use of a small organic compound according to any of the claims 1-2 acting as a Nociceptin receptor ligand with a molecular weight less than 600 or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
4. Use of a small organic compound according to any of the claims 1-3 acting as a Nociceptin receptor ligand with less than 5 amide bonds or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
5. Use of a small organic compound according to any of the claims 1-3 acting as a Nociceptin receptor ligand wherein said compound has no amide bonds or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
6.
7. Use of a compound according to any of the claims 1-5 wherein said compound comprises a triaza-spiro compound acting as a Nociceptin receptor ligand or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
8. Use of a small organic compound according to any of the claims 1-6 acting as a Nociceptin receptor ligand with an IC50 less than 1μM or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
9. A compound of the general formula
wherein
R1 is phenyl, arylalkyl or thienyl, optionally substituted with one or more of halogen, cyano, nitro, trifluoromethyl, C^-alkyl, hydroxy, C^-alkoxy or NR6R8 wherein R6 and R8 independently are hydrogen or C^-alkyl, or R1 is C^-alkyl;
R2 is aminophenyl,
CLg-dialkylaminophenyl, cyanophenyl, C2.6-alkylphenyl, naphthyl, tetrahydronaphthyl, anthryl, furanyl, indanyl, indolyl, isoindolyl, benzothienyl, benzofuranyl, coumarinyl, said groups may be substituted with one or more of halogen, cyano, nitro, trifluoromethyl, C,.6-alkyl, hydroxy, C^-aikoxy, C(O)R7, wherein R7 is -OH, C^-alkoxy or -NR12R13, wherein R12 and R13 independently are hydrogen or C^ alkyl or
R2 is phenyl, phenoxy, benzodioxinyi or cyanodiphenyimethyl, any of which may be substituted with one or more of halogen, cyano, nitro, trifluoromethyl, C^-alkyl, hydroxy, C^-alkoxy, C(0)R7, wherein R7 is -OH, C^-alkoxy or -NR12R13, wherein R12 and R13 independently are hydrogen or C^ alkyl, provided that R1 is not phenyl, R3 is not methyl or hydrogen or R4 is not hydrogen, acetyl, methyl, hy- droxymethyl, ethyl, 2-cyanoethyl, propionyl or methoxymethyl;
R3 is hydrogen, C^-alkyl, phenyl, benzyl or acetyl;
R4 is hydrogen or (CH2)m-(CHR9)-(CH2)p-AR11, wherein m and p independently are 0-4 and R9 is hydrogen, C^-alkyl, phenyl or arylalkyl, R11 is C^-alkyl, hydroxy, C,. 6-alkoxy, guanidino, an amino acid residue or a 2-4 peptidyl residue with a C- terminal group consisting of either OCH3, or NH2 ; R11 can also be a group NR 4R15 wherein R14 and R15 independently are hydrogen, C1 S alkyl, (CH2)qR16 where q can be 0 to 6 and R16 can be a C3-C7 membered cycloalkyl ring, an optionally substituted aromatic or heteroaromatic ring, an aliphatic ring containing one or more heteroatoms, an alkoxy or aryloxy group, an amino or a guanidino group; A is -CH2 or -C=0; provided that when R11 is an amino acid or peptidyl residue, then A is a -C=0 group;
R5 is hydrogen or C^-alkyl;
z is CHR10 wherein R10 is hydrogen, C^-alkyl, phenyl or arylalkyl - or z is C2_8- alkylene, C2_8-alkenylene or C2_8-alkynylene;
n is 1 or 2 or a pharmaceutically acceptable salt thereof.
9. A compound of the general formula
wherein
R1 is phenyl, arylalkyl or thienyl, optionally substituted with one or more of halo- gen, cyano, nitro, trifluoromethyl, C^-alkyl, hydroxy, C^-alkoxy or NR6R8 wherein R6 and R8 independently are hydrogen or C^-alkyl, or R1 is C^-alkyl;
R2 is aminophenyl, C^-monoalkylaminophenyl, C^-dialkylaminophenyl, cyanophenyl, C2.6-alkylphenyl, naphthyl, tetrahydronaphthyl, anthryl, furanyl, indanyl, indolyl, isoindolyl, benzothienyl, benzofuranyl, coumarinyl, said groups may be substituted with one or more of halogen, cyano, nitro, trifluoromethyl, C,.6-alkyl, hydroxy, C^-alkoxy, C(0)R7, wherein R7 is -OH, C^-alkoxy or -NR12R13, wherein R12 and R13 independently are hydrogen or C,.6 alkyl or R2 is phenyl, phenoxy, benzodioxinyl or cyanodiphenyimethyl, any of which may be substituted with one or more of halogen, cyano, nitro, trifluoromethyl, C^-alkyl, hydroxy, C^-alkoxy, C(0)R7, wherein R7 is -OH, C^-alkoxy or -NR12R13, wherein R12 and R13 independently are hydrogen or C^ alkyl, provided that R1 is not phenyl, R3 is not methyl or hydrogen or R4 is not hydrogen, acetyl, methyl, hy- droxymethyl, ethyl, 2-cyanoethyl, propionyl or methoxymethyl;
R3 is hydrogen, C^-alkyl, phenyl, benzyl or acetyl;
R4 is hydrogen or (CH2)m-(CHR9)-(CH2)p-AR11, wherein m and p independently are 0-4 and R9 is hydrogen, C^-alkyl, phenyl or arylalkyl, R1 is C^-alkyl, -OH, an amino acid residue, NR14R15 or C^-alkoxy, wherein R14 and R15 independently are hydrogen or C^ alkyl and A is -CH2 or -C=0;
provided that when R11 is an amino acid residue, then A is a -C=0 group;
R5 is hydrogen or C^-alkyl;
5 z is CHR10 wherein R10 is hydrogen, C^-alkyl, phenyl or arylalkyl - or z is C2.8- alkylene, C2_8-alkenylene or C2.8-alkynylene;
n is 1 or 2 or a pharmaceutically acceptable salt thereof. 0
10. A compound according to claim 8-9 wherein R1 is C^-alkyl, phenyl, arylalkyl or thienyl.
11. A compound according to any of the claims 8-10 wherein
15 R2 is aminophenyl, C^-monoalkylaminophenyl, C^-dialkylaminophenyl, cyanophenyl, C2.6-alkylphenyl, naphthyl, tetrahydronaphthyl, anthryl, furanyl, indanyl, indolyl, isoindolyl, benzothienyl, benzofuranyl, coumahnyl, said groups may be substituted with one or more of fluorine, chlorine, bromine, cyano, nitro, trifluoromethyl, C^-alky!, hydroxy, C^-alkoxy, C(0)R7, wherein R7 is -OH, C^-
20 alkoxy or -NR12R13, wherein R12 and R13 independently are hydrogen or C1-6 alkyl or
R2 is phenyl, phenoxy, benzodioxinyl or cyanodiphenylmethyl, any of which may be substituted with one or more of fluorine, chlorine, bromine, cyano, nitro, trifluoromethyl, C,.6-alkyl, hydroxy, C^-alkoxy, C(0)R7, wherein R7 is -OH, C^-
25 alkoxy or -NR12R13, wherein R12 and R13 independently are hydrogen or C^ alkyl, provided that R1 is not phenyl, R3 is not methyl or hydrogen or R4 is not hydrogen, acetyl, methyl, hydroxymethyl, ethyl, 2-cyanoethyl, propionyl or methoxymethyl or a pharmaceutically acceptable salt thereof.
30 12. A compound according to any of the claims 8-11 wherein
R4 is hydrogen or (CH2)m(CHR9)-(CH2)p-AR11, wherein m and p independently are 0-4 and R9 is hydrogen, C^-alkyl, phenyl or arylalkyl, R11 is -OH, -NR14R15 or C^- alkoxy, wherein R14 and R15 are hydrogen or C^ alkyl and A is C=0 or a pharma- ceutically acceptable salt thereof.
13. A compound according to any of the claims 8-12 selected from the following:
(4-Oxo-8-phenethyl-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl)-acetic acid methyl ester,
{8-[2-(1 ,3-Dioxo-1 ,3-dihydro-isoindol-2-yl)-ethyl]-4-oxo-1 -phenyl-1 ,3,8-triaza- spiro[4.5]dec-3-yl}-acetic acid methyl ester,
[8-(3-Cyano-3,3-diphenyl-propyl)-4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl]- acetic acid methyl ester, [8-(4-Nitro-benzyl)-4-oxo-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester,
[4-Oxo-l -phenyl-8-(3-phenyl-propyl)-1 ,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester,
[4-Oxo-8-(3-phenoxy-propyl)-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester,
[4-Oxo-8-(4-phenoxy-butyl)-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester,
[8-(2,3-Dihydro-benzo[1 , 4]dioxin-2-ylmethyl)-4-oxo-1 -phenyl-1 ,3, 8-triaza- spiro[4.5]dec-3-yl]-acetic acid methyl ester, {8-[5-(1 ,3-Dioxo-1 ,3-dihydro-isoindol-2-yl)-pentyl]-4-oxo-1 -phenyl-1 ,3,8-triaza- spiro[4.5]dec-3-yl}-acetic acid methyl ester,
(8-Naphthalen-1-ylmethyl-4-oxo-1-phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl)-acetic acid methyl ester,
{8-[2-(4-Fluoro-phenoxy)-ethyl]-4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl}- acetic acid methyl ester,
[8-(6,7-Dimethoxy-2-oxo-2H-chromen-4-ylmethyl)-4-oxo-1-phenyl-1 ,3,8-triaza- spiro[4.5]dec-3-yl]-acetic acid methyl ester,
[8-(2-Naphthalen-1-yl-ethyl)-4-oxo-1 -phenyl-1 , 3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester, [8-(3-Cyano-benzyl)-4-oxo-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester,
3-(3-Methoxycarbonylmethyl-4-oxo-1-phenyl-1 ,3,8-triaza-spiro[4.5]dec-8- ylmethyl)-benzoic acid methyl ester,
[8-(4-Bromo-benzyl)-4-oxo-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester,
[8-(3, 4-Dichloro-benzyl)-4-oxo-1 -phenyl-1 , 3, 8-thaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester,
(8-Anthracen-9-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl)-acetic acid methyl ester , 5-Guanidino-2-(S)-[2-(8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]dec-3-yl)-acetylamino]pentanoic acid methylester,
N-(2-Guanidino-ethyl)-2-(8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1 ,3,8-triaza- spiro[4.5]dec-3-yl)-acetamide,
3-(7-Amino-heptyl)-8-naphthalen-1 -ylmethyl-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]decan-4-one,
3-(1 H-lmidazol-4-yl)-2-(S)-[2-(8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1 ,3,8- triaza-spiro[4.5]dec-3-yl)-acetylamino]-propionamide,
5-Guanidino-2-(S)-[2-(8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1 ,3, 8-thaza- spiro[4.5]dec-3-yl)-acetylamino]-pentanoic acid amide, 5-Guanidino-2-(R)-[2-(8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]dec-3-yl)-acetylamino]-pentanoic acid amide,
N-(3-Guanidino-propyl)-2-(8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]dec-3-yl)-acetamide,
3-(5-Amino-pentyl)-8-naphthalen-1 -ylmethyl-1 -phenyl-1 ,3,8-triaza- spiro[4.5]decan-4-one,
N-(3-Amino-propyl)-2-(8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]dec-3-yl)-acetamide,
N-(2-Amino-ethyl)-2-(8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]dec-3-yl)-acetamide, N-[7-(8-Naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl)- heptylj-guanidine,
3-Ethyl-8-naphthalen-1 -ylmethyl-1 -phenyl-1 ,3,8-thaza-spiro[4.5]decan-4-one,
2-(8-Naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl)-N-
(tetrahydro-furan-2-ylmethyl)acetamide, 2-(8-Naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl)-N-[3-
(2-oxo-pyrrolidin-1-yl)-propyl]-acetamide,
6-Amino-2-(S)-[2-(8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3,8-triaza- spiro[4.5]dec-3-yl)-acetylamino]-hexanoic acid amide,
N-Caroamoylmethyl-2-(8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1 ,3,8-triaza- spiro[4.5]dec-3-yl)-acetamide,
2-(S)-[2-(8-Naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3,8-triaza-spiro[4.5]dec-3-yl)- acetylaminoj-phenyi-acetamide,
6-Amino-2-(S)-(2-{6-amino-2-(S)-[2-(8-naphthalen-1-ylmethyl-4-oxo-1-phenyl-
1 ,3,8-triaza-spiro[4.5]dec-3-yl)-acetylamino]-hexanoylamino}-acetylamino)- hexanoic acid amide,
5-Guanidino-2-(S)-{2-[2-(8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]dec-3-yl)-acetylamino]-acetylamino}-pentanoic acid amide,
5-Guanidino-2-(S)-(2-{2-[2-(8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1 ,3,8-triaza- spiro[4.5]dec-3-yl)-acetylamino]-acetylamino}-acetylamino)-pentanoic acid amide, (4-Oxo-8-phenethyl-1-phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl)-acetic acid methyl ester,
[8-(2-Naphthalen-1-yl-ethyl)-4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester,
[8-(4-Bromo-benzyl)-4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester,
[8-(3,4-Dichloro-benzyl)-4-oxo-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester,
5-Guanidino-2-(S)-[2-(8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]dec-3-yl)-acetylamino]-pentanoic acid amide, 5 5-Guanidino-2-(R)-[2-(8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]dec-3-yl)-acetylamino]-pentanoic acid amide or 3-(7-Amino-heptyl)-8-naphthalen-1 -ylmethyl-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]decan-4-one.
10
14. A pharmaceutical composition comprising as active component a compound according to any of the claims 8-13 together with a pharmaceutical acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.
15 15. A pharmaceutical composition suitable for use in the treatment of migraine, non insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation, incontinence and/or vasomotor disturbances comprising an amount of compound according to any of the claims 8-13 together with a pharmaceutical carrier or diluent.
20
16. A pharmaceutical composition according to any of the claims 14 or 15 wherein it is in a form of an oral dosage unit or a form suitable for oral, nasal, transdermal, pulmonal parenteral dosage unit containing 0.1 to about 1000 mg per patient per day.
25
17. Use of a compound according to any of the claims 8-13 for the preparation of a medicament for treatment of migraine, non insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation, incontinence and/or vasomotor disturbances.
30
18. Use of a compound according to any of the claims 8-13 for the preparation of a medicament for treatment of vasomotor disturbances, especially hot flushes.
19. A method of treating hot flushes in a subject in need of such treatment
5 comprising the step of administering to said object an amount of a compound according to any of the claims 8-13which is effective for the alleviation of such ailment.
20. A method of treating hot flushes in a subject in need of such treatment 10 comprising the step of administering to said object an amount of a compound according to any of the claims 8-13 which is effective for the alleviation of such ailment in the form of a pharmaceutical composition thereof, in which it is present together with a pharmaceutically acceptable carrier or diluent.
15 21. Use of a compound of the general formula
wherein
20 R is phenyl, arylalkyl or thienyl, optionally substituted with one or more of halo- gene, cyano, nitro, trifluoromethyl, C^-alkyl, hydroxy, C^-alkoxy or NR6R8 wherein R6 and R8 independently are hydrogen or C^-alkyl, or R1 is C^-alkyl; R2 is phenyl, phenoxy, benzodioxinyl, cyanodiphenylmethyl, aminophenyl, C.,_6-
25 monoalkylammophenyl, C^-dialkylaminophenyl, naphthyl, tetrahydronaphthyl, anthryl, furanyl, indanyl, indolyl, isoindolyl, benzothienyl, benzofuranyl, coumari-
nyl, said groups may be substituted with one or more of halogen, cyano, nitro, trifluoromethyl, C^-alkyl, hydroxy, C^-alkoxy, C(0)R7, wherein R7 is -OH, C^- alkoxy or -NR12R13, wherein R12 and R13 independently are hydrogen or C^ alkyl;
R3 is hydrogen, C^-alky!, phenyl, benzyl or acetyl;
R4 is hydrogen or (CH2)m-(CHR9)-(CH2)p-AR11, wherein m and p independently are 0-4 and R9 is hydrogen, C^-alkyl, phenyl or arylalkyl, R11 is C^-alkyl, hydroxy, C,. 6-alkoxy, guanidino, an amino acid residue or a 2-4 peptidyl residue with a C- terminal group consisting of either OCH3, or NH2 ; R11 can also be a group NR14R15 wherein R14 and R15 independently are hydrogen, C,.β alkyl, (CH2)qR16 where q can be 0 to 6 and R16can be a C3-C7 membered cycloalkyl ring, an optionally substituted aromatic or heteroaromatic ring, an aliphatic ring containing one or more heteroatoms, an alkoxy or aryloxy group, an amino or a guanidino group; A is -CH2 or -C=0; provided that when R11 is an amino acid or peptidyl residue, then A is a -C=0 group;
R5 is hydrogen or C1_4-alkyl;
z is CHR10 wherein R10 is hydrogen, C^-alkyl, phenyl or arylalkyl - or z is C2.8- alkylene, C2_8-alkenylene or C2.8-alkynylene;
n is 1 or 2 or a pharmaceutically acceptable salt thereof for the treatment of migraine, non insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation, incontinence, vasomotor disturbances, in particular the peripheral vasomotor effects known as hot flushes or hot flashes and/or for alleviating symptoms of drug withdrawal, in particular abstinence symptoms occurring during withdrawal from abusive drugs.
AMENDED CLAIMS
[received by the International Bureau on 18 October 1999 (18.10.99); Original claims 1-21 replaced by new claims 1-21; (11 pages)]
1. Use of a small organic compound acting as an opioid receptor ligand for the preparation of a pharmaceutical composition for the treatment of a disease selected from migraine, non insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation, incontinence, vasomotor disturbances, in particular the peripheral vasomotor effects known as hot flushes or hot flashes and/or for alleviating symptoms of drug withdrawal, in particular abstinence symptoms occurring during withdrawal from abusive drugs.
2. Use of a small organic compound according to claim 1 acting as a Nociceptin receptor ligand with a molecular weight of less than 1000 or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
3. Use of a small organic compound according to any of the claims 1 -2 acting as a Nociceptin receptor ligand with a molecular weight less than 600 or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
4. Use of a small organic compound according to any of the claims 1-3 acting as a Nociceptin receptor ligand with less than 5 amide bonds or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
5. Use of a small organic compound according to any of the claims 1 -3 acting as a Nociceptin receptor ligand wherein said compound has no amide bonds or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
6. Use of a compound according to any of the claims 1 -5 wherein said compound comprises a triaza-spiro compound acting as a Nociceptin receptor ligand or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
7. Use of a small organic compound according to any of the claims 1-6 acting as a Nociceptin receptor ligand with an ICso less than 1 μM or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical composition for the treatment of vasomotor disturbances.
8. A compound of the general formula
wherein
R1 is phenyl, arylalkyl or thienyl, optionally substituted with one or more of halogen, cyano, nitro, trifluoromethyl, C1-6-alkyl, hydroxy, Cι-6-alkoxy or NR6R8 wherein R6 and R8 independently are hydrogen or Cι-6-alkyl, or R is Cι-6-alkyl;
R2 is aminophenyl, C..6-monoalkylaminophenyl, Cι-6-dialkylaminophenyl, cyanophenyl, C2-6-alkylphenyl, naphthyl, tetrahydronaphthyl, anthryl, furanyl, indanyl, indolyl, isoindolyl, benzothienyl, benzofuranyl, coumarinyi, said groups may be substituted with one or more of halogen, cyano, nitro, trifluoromethyl, Ci-e-alkyl, hydroxy, Cι-6-alkoxy, C(0)R7, wherein R7 is -OH, d-6-alkoxy or -NR12R13, wherein R12 and R13 independently are hydrogen or d-β alkyl or
R2 is phenyl, phenoxy, benzodioxinyl or cyanodiphenylmethyl, any of which may be substituted with one or more of halogen, cyano, nitro, trifluoromethyl, d-e-
alkyl, hydroxy, d-e-alkoxy , C(0)R7, wherein R7 is -OH, C1-6-alkoxy or -NR12R13, wherein R12 and R13 independently are hydrogen or C1-6 alkyl, provided that R1 is not phenyl, R3 is not methyl or hydrogen or R4 is not hydrogen, acetyl, methyl, hydroxymethyl, ethyl, 2-cyanoethyl, propionyl or methoxymethyl;
R3 is hydrogen, C1-6-alkyl, phenyl, benzyl or acetyl;
R4 is hydrogen or (CH2)m-(CHR9)-(CH2)p-AR11, wherein m and p independently are 0-4 and R9 is hydrogen, d-e-alkyl, phenyl or arylalkyl, R11 is C1-6-alkyl, hy- droxy, d-e-alkoxy, guanidino, an amino acid residue or a 2-4 peptidyl residue with a C-terminal group consisting of either OCH3, or NH2 ; R11 can also be a group NR14R15 wherein R14 and R15 independently are hydrogen, C1-6 alkyl, (CH2)qR16 where q can be 0 to 6 and R16 can be a C3-C7 membered cycloalkyl ring, an optionally substituted aromatic or heteroaromatic ring, an aliphatic ring containing one or more heteroatoms, an alkoxy or aryloxy group, an amino or a guanidino group; A is -CH2 or -C=0; provided that when R11 is an amino acid or peptidyl residue, then A is a -C=0 group;
R5 is hydrogen or d-4-alkyl;
z is CHR10 wherein R10 is hydrogen, Cι-6-alkyl, phenyl or arylalkyl - or z is C2-8- alkylene, C2-8-alkenylene or C2-8-alkynylene;
n is 1 or 2 or a pharmaceutically acceptable salt thereof.
9. A compound of the general formula
wherein
R1 is phenyl, arylalkyl or thienyl, optionally substituted with one or more of halo- gen, cyano, nitro, trifluoromethyl, d-e-alkyl, hydroxy, Cι-6-alkoxy or NR6R8 wherein R6 and R8 independently are hydrogen or Cι-6-alkyl, or R1 is d-e-alkyl;
R _2 : is aminophenyl, Ci-e-monoalkylaminophenyl, Ci-e-dialkylaminophenyl, cyanophenyl, C2-6-alkylphenyl, naphthyl, tetrahydronaphthyl, anthryl, furanyl, indanyl, indolyl, isoindolyl, benzothienyl, benzofuranyl, coumarinyl, said groups may be substituted with one or more of halogen, cyano, nitro, trifluoromethyl, Cι-6-alkyl, hydroxy, Cι.6-alkoxy, C(0)R7, wherein R7 is -OH, Cι-6-alkoxy or -NR12R13, wherein R12 and R13 independently are hydrogen or C1-6 alkyl or R2 is phenyl, phenoxy, benzodioxinyl or cyanodiphenylmethyl, any of which may be substituted with one or more of halogen, cyano, nitro, trifluoromethyl, d-e- alkyl, hydroxy, d-e-alkoxy, C(0)R7, wherein R7 is -OH, Cι-6-alkoxy or -NR12R13, wherein R12 and R13 independently are hydrogen or C1-6 alkyl, provided that R1 is not phenyl, R3 is not methyl or hydrogen or R4 is not hydrogen, acetyl, methyl, hydroxymethyl, ethyl, 2-cyanoethyl, propionyl or methoxymethyl;
R3 is hydrogen, Cι-6-alkyl, phenyl, benzyl or acetyl;
R4 is hydrogen or (CH2)m-(CHR9)-(CH2)p-AR11, wherein m and p independently are 0-4 and R9 is hydrogen, Cι-6-alkyl, phenyl or arylalkyl, R11 is Ci-6-alkyl, -OH, an amino acid residue, NR14R15 or Cι-6-alkoxy, wherein R14 and R15 independently are hydrogen or C1-6 alkyl and A is -CH2 or -C=0; provided that when R11 is an amino acid residue, then A is a -C=0 group;
R5 is hydrogen or Cι-4-alkyl;
z is CHR10 wherein R10 is hydrogen, Ci-6-alkyl, phenyl or arylalkyl - or z is C2^- 5 alkylene, C2.8-alkenylene or C2.8-alkynylene;
n is 1 or 2 or a pharmaceutically acceptable salt thereof.
10 10. A compound according to claim 8-9 wherein R1 is d-e-alkyl, phenyl, arylalkyl or thienyl.
11. A compound according to any of the claims 8-10 wherein
R2 is aminophenyl, d-e-monoalkylaminophenyl, Ci-e-dialkylaminophenyl, cya- 15 nophenyl, C2.6-alkylphenyl, naphthyl, tetrahydronaphthyl, anthryl, furanyl, indanyl, indolyl, isoindolyl, benzothienyl, benzofuranyl, coumarinyl, said groups may be substituted with one or more of fluorine, chlorine, bromine, cyano, nitro, trifluoromethyl, Cι-6-alkyl, hydroxy, Cι-6-alkoxy, C(0)R7, wherein R7 is -OH, d-e- alkoxy or -NR12R13, wherein R12 and R13 independently are hydrogen or d-e alkyl 20 or
R2 is phenyl, phenoxy, benzodioxinyl or cyanodiphenylmethyi, any of which may be substituted with one or more of fluorine, chlorine, bromine, cyano, nitro, trifluoromethyl, Cι-6-alkyl, hydroxy, d-e-alkoxy, C(0)R7, wherein R7 is -OH, d-e- alkoxy or -NR12R13, wherein R12 and R13 independently are hydrogen or C1-6 alkyl, 25 provided that R1 is not phenyl, R3 is not methyl or hydrogen or R4 is not hydrogen, acetyl, methyl, hydroxymethyl, ethyl, 2-cyanoethyl, propionyl or methoxymethyl or a pharmaceutically acceptable salt thereof.
12. A compound according to any of the claims 8-11 wherein
30
R4 is hydrogen or (CH2)m(CHR9)-(CH2)p-AR11, wherein m and p independently are 0-4 and R9 is hydrogen, Cι-6-alkyl, phenyl or arylalkyl, R11 is -OH, -NR14R15 or d-e- alkoxy, wherein R14 and R15 are hydrogen or C1-6 alkyl and A is C=0 or a pharmaceutically acceptable salt thereof.
13. A compound according to any of the claims 8-12 selected from the following:
(4-0xo-8-phenethyl-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl)-acetic acid methyl ester, {8-[2-(1 ,3-Dioxo-1 ,3-dihydro-isoindol-2-yl)-ethyl]-4-oxo-1 -phenyl-1 ,3,8-triaza- spiro[4.5]dec-3-yl}-acetic acid methyl ester,
[8-(3-Cyano-3,3-diphenyl-propyl)-4-oxo-1 -phenyl-1 ,3, 8-triaza-spiro[4.5]dec-3-yl]- acetic acid methyl ester,
[8-(4-Nitro-benzyl)-4-oxo-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester,
[4-Oxo-l -phenyl-8-(3-phenyl-propyl)-1 ,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester,
[4-Oxo-8-(3-phenoxy-propyl)-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester, [4-Oxo-8-(4-phenoxy-butyl)-1 -phenyl-1 ,3, 8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester,
[8-(2,3-Dihydro-benzo[1 ,4]dioxin-2-ylmethyl)-4-oxo-1 -phenyl-1 ,3,8-triaza- spiro[4.5]dec-3-yl]-acetic acid methyl ester,
{8-[5-(1 ,3-Dioxo-1 ,3-dihydro-isoindol-2-yl)-pentyl]-4-oxo-1 -phenyl-1 ,3,8-triaza- spiro[4.5]dec-3-yl}-acetic acid methyl ester,
(8-Naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3,8-triaza-spiro[4.5]dec-3-yl)-acetic acid methyl ester,
{8-[2-(4-Fluoro-phenoxy)-ethyl]-4-oxo-1 -phenyl-1 , 3,8-triaza-spiro[4.5]dec-3-yl}- acetic acid methyl ester,
[8-(6,7-Dimethoxy-2-oxo-2H-chromen-4-ylmethyl)-4-oxo-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]dec-3-yl]-acetic acid methyl ester,
[8-(2-Naphthalen-1 -yl-ethyl)-4-oxo-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester, [8-(3-Cyano-benzyl)-4-oxo-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester,
3-(3-Methoxycarbonylmethyl-4-oxo-1 -phenyl-1 , 3,8-triaza-spiro[4.5]dec-8- ylmethyl)-benzoic acid methyl ester,
[8-(4-Bromo-benzyl)-4-oxo-1 -phenyl-1 ,3, 8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester,
[8-(3,4-Dichloro-benzyl)-4-oxo-1 -phenyl-1 , 3, 8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester,
(8-Anthracen-9-ylmethyl-4-oxo-1 -phenyl-1 , 3,8-triaza-spiro[4.5]dec-3-yl)-acetic acid methyl ester , 5-Guanidino-2-(S)-[2-(8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3,8-triaza- spiro[4.5]dec-3-yl)-acetylamino]pentanoic acid methylester,
N-(2-Guanidino-ethyl)-2-(8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1 ,3,8-triaza- spiro[4.5]dec-3-yl)-acetamide,
3-(7-Amino-heptyl)-8-naphthalen-1 -ylmethyl-1 -phenyl-1 , 3,8-triaza- spiro[4.5]decan-4-one,
3-(1 H-lmidazol-4-yl)-2-(S)-[2-(8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1 ,3,8- triaza-spiro[4.5]dec-3-yl)-acetylamino]-propionamide,
5-Guanidino-2-(S)-[2-(8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1 ,3,8-triaza- spiro[4.5]dec-3-yl)-acetylamino]-pentanoic acid amide, 5-Guanidino-2-(R)-[2-(8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1 ,3,8-triaza- spiro[4.5]dec-3-yl)-acetylamino]-pentanoic acid amide,
N-(3-Guanidino-propyl)-2-(8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1 ,3,8-triaza- spiro[4.5]dec-3-yl)-acetamide,
3-(5-Amino-pentyl)-8-naphthalen-1 -ylmethyl-1 -phenyl-1 ,3,8-triaza- spiro[4.5]decan-4-one,
N-(3-Amino-propyl)-2-(8-naphthalen-1 -ylmethy!-4-oxo-1 -phenyl-1 ,3,8-triaza- spiro[4.5]dec-3-yl)-acetamide,
N-(2-Amino-ethyl)-2-(8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3, 8-triaza- spiro[4.5]dec-3-yl)-acetamide, N-[7-(8-Naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl)- heptyl]-guanidine,
3-Ethyl-8-naphthalen-1 -ylmethyl-1 -phenyl-1 ,3,8-triaza-spiro[4.5]decan-4-one,
2-(8-Naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3,8-triaza-spiro[4.5]dec-3-yl)-N-
(tetrahydro-furan-2-ylmethyl)acetamide, 2-(8-Naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3,8-triaza-spiro[4.5]dec-3-yl)-N-[3-
(2-oxo-pyrrolidin-1-yl)-propyl]-acetamide,
6-Amino-2-(S)-[2-(8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1 ,3,8-triaza- spiro[4.5]dec-3-yl)-acetylamino]-hexanoic acid amide,
N-Carbamoylmethyl-2-(8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3,8-triaza- spiro[4.5]dec-3-yl)-acetamide,
2-(S)-[2-(8-Naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl)- acetylaminoj-phenyl-acetamide,
6-Amino-2-(S)-(2-{6-amino-2-(S)-[2-(8-naphthalen-1-ylmethyl-4-oxo-1-phenyl-
1 ,3,8-triaza-spiro[4.5]dec-3-yl)-acetylamino]-hexanoylamino}-acetylamino)- hexanoic acid amide,
5-Guanidino-2-(S)-{2-[2-(8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1 ,3,8-triaza- spiro[4.5]dec-3-yl)-acetylamino]-acetylamino}-pentanoic acid amide,
5-Guanidino-2-(S)-(2-{2-[2-(8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1 ,3,8-triaza- spiro[4.5]dec-3-yl)-acetylamino]-acetylamino}-acetylamino)-pentanoic acid amide, (4-Oxo-8-phenethyl-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl)-acetic acid methyl ester,
[8-(2-Naphthalen-1 -yl-ethyl)-4-oxo-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester,
[8-(4-Bromo-benzyl)-4-oxo-1 -phenyl-1 ,3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester,
[8-(3,4-Dichloro-benzyl)-4-oxo-1 -phenyl-1 , 3,8-triaza-spiro[4.5]dec-3-yl]-acetic acid methyl ester,
5-Guanidino-2-(S)-[2-(8-naphthalen-1 -ylmethyl-4-oxo-1 -phenyl-1 ,3,8-triaza- spiro[4.5]dec-3-yl)-acetylamino]-pentanoic acid amide, 5-Guanidino-2-(R)-[2-(8-naphthalen-1-ylmethyl-4-oxo-1 -phenyl-1 , 3,8-triaza- spiro[4.5]dec~3-yl)-acetylamino]-pentanoic acid amide or 3-(7-Amino-heptyl)-8-naphthalen-1 -ylmethyl-1 -phenyl-1 ,3,8-triaza- spiro[4.5]decan-4-one.
10
14. A pharmaceutical composition comprising as active component a compound according to any of the claims 8-13 together with a pharmaceutical acceptable acid addition salt thereof and a pharmaceutically acceptable carrier or diluent.
15 15. A pharmaceutical composition suitable for use in the treatment of migraine, non insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation, incontinence and/or vasomotor disturbances comprising an amount of compound according to any of the claims 8-13 together with a pharmaceutical carrier or diluent.
20
16. A pharmaceutical composition according to any of the claims 14 or 15 wherein it is in a form of an oral dosage unit or a form suitable for oral, nasal, transdermal, pulmonal parenteral dosage unit containing 0.1 to about 1000 mg per patient per day.
25
17. Use of a compound according to any of the claims 8-13 for the preparation of a medicament for treatment of migraine, non insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation, incontinence and/or vasomotor disturbances.
30
18. Use of a compound according to any of the claims 8-13 for the preparation of a medicament for treatment of vasomotor disturbances, especially hot flushes.
19. A method of treating hot flushes in a subject in need of such treatment
5 comprising the step of administering to said object an amount of a compound according to any of the claims 8-13which is effective for the alleviation of such ailment.
20. A method of treating hot flushes in a subject in need of such treatment
1 o comprising the step of administering to said object an amount of a compound according to any of the claims 8-13 which is effective for the alleviation of such ailment in the form of a pharmaceutical composition thereof, in which it is present together with a pharmaceutically acceptable carrier or diluent.
15 21. Use of a compound of the general formula
wherein
20 R1 is phenyl, arylalkyl or thienyl, optionally substituted with one or more of halo- gene, cyano, nitro, trifluoromethyl, d-e-alkyl, hydroxy, Cι-6-alkoxy or NR6R8 wherein R6 and R8 independently are hydrogen or Cι-6-alkyl, or R1 is Cι-6-alkyl; R2 is phenyl, phenoxy, benzodioxinyl, cyanodiphenylmethyl, aminophenyl, C1-6-
25 monoalkylaminophenyl, Ci-e-dialkylaminophenyl, naphthyl, tetrahydronaphthyl, anthryl, furanyl, indanyl, indolyl, isoindolyl, benzothienyl, benzofuranyl, coumarinyl, said groups may be substituted with one or more of halogen, cyano, nitro,
trifluoromethyl, d-β-alkyl, hydroxy, Cι-6-alkoxy, C(0)R7, wherein R7 is -OH, d-β- alkoxy or -NR12R13, wherein R12 and R13 independently are hydrogen or C1-6 alkyl;
R3 is hydrogen, Cι-6-alkyl, phenyl, benzyl or acetyl;
R4 is hydrogen or (CH2)m-(CHR9)-(CH2)p-AR11, wherein m and p independently are 0-4 and R9 is hydrogen, Cι-6-alkyl, phenyl or arylalkyl, R11 is d-e-alkyl, hydroxy, Ci-6-alkoxy, guanidino, an amino acid residue or a 2-4 peptidyl residue with a C-terminal group consisting of either OCH3, or NH2 ; R11 can also be a group NR1 R15 wherein R14 and R15 independently are hydrogen, C.-β alkyl, (CH2)qR16 where q can be 0 to 6 and R16 can be a C3-C7 membered cycloalkyl ring, an optionally substituted aromatic or heteroaromatic ring, an aliphatic ring containing one or more heteroatoms, an alkoxy or aryloxy group, an amino or a guanidino group; A is -CH2 or -C=0; provided that when R11 is an amino acid or peptidyl residue, then A is a -C=0 group;
Rs is hydrogen or Cι. -alkyl;
z is CHR10 wherein R10 is hydrogen, Cι-6-alkyl, phenyl or arylalkyl - or z is CM- alkylene, C2-8-alkenylene or C2-8-alkynylene;
n is 1 or 2 or a pharmaceutically acceptable salt thereof for the treatment of migraine, non insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation, incontinence, vasomotor disturbances, in particular the peripheral vasomotor effects known as hot flushes or hot flashes and/or for alleviating symptoms of drug withdrawal, in particular abstinence symptoms occurring during withdrawal from abusive drugs.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU38099/99A AU3809999A (en) | 1998-05-18 | 1999-05-14 | Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes |
| JP2000549615A JP2002515503A (en) | 1998-05-18 | 1999-05-14 | Novel 1,3,8-triazaspiro [4,5] decanone with high affinity for opioid receptor subtypes |
| EP99920561A EP1080091A1 (en) | 1998-05-18 | 1999-05-14 | Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes |
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK68198 | 1998-05-18 | ||
| DK71198 | 1998-05-20 | ||
| DK72998 | 1998-05-26 | ||
| DKPA199800729 | 1998-05-26 | ||
| DKPA199800927 | 1998-07-10 | ||
| DKPA199800927 | 1998-07-10 | ||
| DK0711/98 | 1999-01-29 | ||
| DKPA199900111 | 1999-01-29 | ||
| DKPA199900111 | 1999-01-29 | ||
| DK0681/98 | 1999-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1999059997A1 true WO1999059997A1 (en) | 1999-11-25 |
Family
ID=27512746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/DK1999/000266 WO1999059997A1 (en) | 1998-05-18 | 1999-05-14 | Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1080091A1 (en) |
| JP (1) | JP2002515503A (en) |
| AU (1) | AU3809999A (en) |
| WO (1) | WO1999059997A1 (en) |
Cited By (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0997464A1 (en) * | 1998-10-23 | 2000-05-03 | Pfizer Inc. | 1,3,8-Triazaspiro[4,5] decanone compounds as orl1-receptor agonists |
| WO2001036418A1 (en) * | 1999-11-17 | 2001-05-25 | Novo Nordisk A/S | Novel triazaspirodecanones with high affinity for opioid receptor subtypes |
| WO2001039723A2 (en) * | 1999-12-06 | 2001-06-07 | Euro-Celtique, S.A. | Triazospiro compounds having nociceptin receptor affinity |
| WO2001046192A1 (en) * | 1999-12-22 | 2001-06-28 | Meiji Seika Kaisha, Ltd. | SPIRO COMPOUNDS USEFUL AS OPIOID δ RECEPTOR AGONIST |
| WO2002013759A2 (en) * | 2000-08-15 | 2002-02-21 | Cpd Llc | Method of treating the syndrome of type 2 diabetes in humans |
| EP1256575A1 (en) * | 2000-02-18 | 2002-11-13 | Meiji Seika Kaisha Ltd. | Phenoxyalkylamine derivatives useful as opioid delta receptor agonists |
| WO2002100861A1 (en) * | 2001-06-13 | 2002-12-19 | Akzo Nobel N.V. | 1-(3-phenyloxypropyl)piperidine derivatives |
| WO2003082333A1 (en) | 2002-03-29 | 2003-10-09 | Mitsubishi Pharma Corporation | Remedy for sleep disturbance |
| US6635653B2 (en) | 2001-04-18 | 2003-10-21 | Euro-Celtique S.A. | Spiropyrazole compounds |
| WO2004022558A2 (en) * | 2002-09-09 | 2004-03-18 | Janssen Pharmaceutica, N.V. | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders |
| EP1402899A1 (en) * | 2001-05-08 | 2004-03-31 | Toray Industries, Inc. | Remedies for sepsis |
| US6777421B2 (en) | 2001-04-10 | 2004-08-17 | Ortho-Mcneil Pharmaceutical, Inc. | 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
| WO2004104004A2 (en) * | 2003-05-23 | 2004-12-02 | Zealand Pharma A/S | Triaza-spiro compounds as nociceptin analogues and uses thereof |
| US6828440B2 (en) | 2001-04-18 | 2004-12-07 | Euro-Celtique, S.A. | Spiroindene and spiroindane compounds |
| US6846831B2 (en) | 2000-08-15 | 2005-01-25 | Cpd, Llc | Method of treating the syndrome of lipodystrophy |
| US6861421B2 (en) | 2001-04-18 | 2005-03-01 | Euro-Celtique S.A | Nociceptin analogs |
| US6867222B2 (en) | 2001-04-18 | 2005-03-15 | Euro-Celtique, S.A. | Nociceptin analogs |
| US6872733B2 (en) | 2001-04-18 | 2005-03-29 | Euro-Celtique S.A. | Benzimidazolone compounds |
| US6919310B2 (en) | 2000-08-15 | 2005-07-19 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US6969712B2 (en) | 2000-11-15 | 2005-11-29 | Banyu Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| US6979436B2 (en) | 1999-11-19 | 2005-12-27 | Palatin Technologies, Inc. | Opioid metallopeptide compositions and methods |
| US6984664B2 (en) | 1999-12-06 | 2006-01-10 | Euro-Celtique, S.A. | Tertiary amino compounds having opioid receptor affinity |
| US6995168B2 (en) | 2002-05-31 | 2006-02-07 | Euro-Celtique S.A. | Triazaspiro compounds useful for treating or preventing pain |
| US7125877B2 (en) | 2002-05-14 | 2006-10-24 | Banyu Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| US7456198B2 (en) | 1999-12-06 | 2008-11-25 | Purdue Pharma L.P. | Benzimidazole compounds having nociceptin receptor affinity |
| WO2011160084A1 (en) * | 2010-06-18 | 2011-12-22 | Altos Therapeutics, LLC | D2 antagonists, methods of synthesis and methods of use |
| US8354434B2 (en) | 2006-01-30 | 2013-01-15 | Purdue Pharma L.P. | Cyclourea compounds as calcium channel blockers |
| US8399474B2 (en) | 2006-10-20 | 2013-03-19 | Neurendo Pharma, Llc | Method of restoring the incretin effect |
| US8703948B2 (en) | 2006-11-28 | 2014-04-22 | Janssen Pharmaceutica Nv | Salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one |
| US8741916B2 (en) | 2007-04-09 | 2014-06-03 | Janssen Pharmaceutica Nv | 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the ORL-1 receptor |
| US10034871B2 (en) | 2014-11-07 | 2018-07-31 | Regents Of The University Of Minnesota | Salts and compositions useful for treating disease |
| US11472777B2 (en) * | 2015-09-14 | 2022-10-18 | The National Institute for Biotechnology in the Negev Ltd. | Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1567164E (en) * | 2002-11-26 | 2009-03-31 | Alexza Pharmaceuticals Inc | Use of loxapine for the manufacture of a medicament for the treatment of pain |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3238216A (en) * | 1963-06-20 | 1966-03-01 | Res Lab Dr C Janssen N V | Substituted 1, 3, 8-triaza-spiro (4, 5) decanes |
| GB1043141A (en) * | 1962-06-22 | 1966-09-21 | Res Lab Dr C Janssen Nv | Substituted-4-oxo-1, 3, 8-triazaspiro (4, 5) decanes and their therapeutically active non-toxic acid addition salts and the preparation thereof |
| US3723441A (en) * | 1968-10-28 | 1973-03-27 | Smith Kline French Lab | Benzoheterocyclicalkyl derivatives of 1-phenyl-1,3,8, triazaspiro (4,5) decan-4-one |
| JPS491573A (en) * | 1972-04-28 | 1974-01-08 | ||
| US3863011A (en) * | 1973-06-28 | 1975-01-28 | American Home Prod | Process for treating neuroendocrinopathic diseases employing pimozide |
| US3923993A (en) * | 1973-06-28 | 1975-12-02 | American Home Prod | Process for treating neuroendocrinopathic diseases employing fluspirilene |
| GB1547597A (en) * | 1975-07-14 | 1979-06-20 | Squibb & Sons Inc | 1,3,8-triazaspiro(4.5)decan-4-one derivatives |
| WO1991013622A1 (en) * | 1990-03-16 | 1991-09-19 | Beth Israel Hospital Association | Use of spiperone as an immunosuppressant and anti-inflammatory agent |
| WO1993012789A1 (en) * | 1991-12-27 | 1993-07-08 | Beth Israel Hospital | Use of spiperone or spiperone derivatives as immunosuppressant agents |
-
1999
- 1999-05-14 EP EP99920561A patent/EP1080091A1/en not_active Withdrawn
- 1999-05-14 JP JP2000549615A patent/JP2002515503A/en active Pending
- 1999-05-14 WO PCT/DK1999/000266 patent/WO1999059997A1/en not_active Application Discontinuation
- 1999-05-14 AU AU38099/99A patent/AU3809999A/en not_active Abandoned
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1043141A (en) * | 1962-06-22 | 1966-09-21 | Res Lab Dr C Janssen Nv | Substituted-4-oxo-1, 3, 8-triazaspiro (4, 5) decanes and their therapeutically active non-toxic acid addition salts and the preparation thereof |
| US3238216A (en) * | 1963-06-20 | 1966-03-01 | Res Lab Dr C Janssen N V | Substituted 1, 3, 8-triaza-spiro (4, 5) decanes |
| US3723441A (en) * | 1968-10-28 | 1973-03-27 | Smith Kline French Lab | Benzoheterocyclicalkyl derivatives of 1-phenyl-1,3,8, triazaspiro (4,5) decan-4-one |
| JPS491573A (en) * | 1972-04-28 | 1974-01-08 | ||
| US3863011A (en) * | 1973-06-28 | 1975-01-28 | American Home Prod | Process for treating neuroendocrinopathic diseases employing pimozide |
| US3923993A (en) * | 1973-06-28 | 1975-12-02 | American Home Prod | Process for treating neuroendocrinopathic diseases employing fluspirilene |
| GB1547597A (en) * | 1975-07-14 | 1979-06-20 | Squibb & Sons Inc | 1,3,8-triazaspiro(4.5)decan-4-one derivatives |
| WO1991013622A1 (en) * | 1990-03-16 | 1991-09-19 | Beth Israel Hospital Association | Use of spiperone as an immunosuppressant and anti-inflammatory agent |
| WO1993012789A1 (en) * | 1991-12-27 | 1993-07-08 | Beth Israel Hospital | Use of spiperone or spiperone derivatives as immunosuppressant agents |
Non-Patent Citations (7)
| Title |
|---|
| ANTHONY E. LANZILOTTI ET AL: "Stereoselective Reduction of Some Indoles with Triethylsilane-Trifluoracetic Acid1", J. ORG. CHEM., vol. 44, no. 26, 1979, pages 4809 - 4813, XP000857887 * |
| ARCH. PHARM., vol. 330, no. (1/2), 1997, pages 25 - 28, SEE REG. NO. 189209-03-8 * |
| CHEMICAL ABSTRACTS, vol. 126, no. 24, 16 January 1997, Columbus, Ohio, US; abstract no. 312189G, DUKIC SLADJANA ET AL: "Synthesis and dopaminergic properties of 3- and 4-substituted 1-(2-(5-(1H-benzimidazole-2-thione))ethyl)-piperidines and related compounds" page 73; XP002921484 * |
| CHEMICAL ABSTRACTS, vol. 70, no. 17, 28 April 1969, Columbus, Ohio, US; abstract no. 77149H, LECOLIER S.: "LCAO method applied to the determination and synthesis of anthracenes with neuroleptic activity" page 264; XP002921485 * |
| CHEMICAL ABSTRACTS, vol. 78, no. 9, 5 March 1973, Columbus, Ohio, US; abstract no. 58426V, page 523; XP002921483 * |
| CHEMICAL ABSTRACTS, vol. 81, no. 5, 5 August 1974, Columbus, Ohio, US; abstract no. 25674H, page 435; XP002921482 * |
| CHIM. THER., vol. 3, no. (3), 1968, pages 193 - 199, SEE REG. NO. 22682-90-2 AND 22753-42-0 * |
Cited By (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0997464A1 (en) * | 1998-10-23 | 2000-05-03 | Pfizer Inc. | 1,3,8-Triazaspiro[4,5] decanone compounds as orl1-receptor agonists |
| WO2001036418A1 (en) * | 1999-11-17 | 2001-05-25 | Novo Nordisk A/S | Novel triazaspirodecanones with high affinity for opioid receptor subtypes |
| US6979436B2 (en) | 1999-11-19 | 2005-12-27 | Palatin Technologies, Inc. | Opioid metallopeptide compositions and methods |
| US7456198B2 (en) | 1999-12-06 | 2008-11-25 | Purdue Pharma L.P. | Benzimidazole compounds having nociceptin receptor affinity |
| US6984664B2 (en) | 1999-12-06 | 2006-01-10 | Euro-Celtique, S.A. | Tertiary amino compounds having opioid receptor affinity |
| US7678809B2 (en) | 1999-12-06 | 2010-03-16 | Purdue Pharma L.P. | Benzimidazole compounds having nociceptin receptor affinity |
| WO2001039723A3 (en) * | 1999-12-06 | 2004-10-28 | Euro Celtique Sa | Triazospiro compounds having nociceptin receptor affinity |
| US6686370B2 (en) | 1999-12-06 | 2004-02-03 | Euro-Celtique S.A. | Triazospiro compounds having nociceptin receptor affinity |
| JP2007126474A (en) * | 1999-12-06 | 2007-05-24 | Euro-Celtique Sa | Triazospiro compound having nociceptin receptor affinity |
| WO2001039723A2 (en) * | 1999-12-06 | 2001-06-07 | Euro-Celtique, S.A. | Triazospiro compounds having nociceptin receptor affinity |
| WO2001046192A1 (en) * | 1999-12-22 | 2001-06-28 | Meiji Seika Kaisha, Ltd. | SPIRO COMPOUNDS USEFUL AS OPIOID δ RECEPTOR AGONIST |
| EP1256575A1 (en) * | 2000-02-18 | 2002-11-13 | Meiji Seika Kaisha Ltd. | Phenoxyalkylamine derivatives useful as opioid delta receptor agonists |
| EP1256575A4 (en) * | 2000-02-18 | 2003-03-05 | Meiji Seika Kaisha | Phenoxyalkylamine derivatives useful as opioid delta receptor agonists |
| US6916822B2 (en) | 2000-02-18 | 2005-07-12 | Meiji Seika Kaisha, Ltd. | Phenoxyalkylamine derivatives useful as opioid δ receptor agonists |
| WO2002013759A3 (en) * | 2000-08-15 | 2003-07-10 | Cpd Llc | Method of treating the syndrome of type 2 diabetes in humans |
| US6846831B2 (en) | 2000-08-15 | 2005-01-25 | Cpd, Llc | Method of treating the syndrome of lipodystrophy |
| US6919310B2 (en) | 2000-08-15 | 2005-07-19 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| WO2002013759A2 (en) * | 2000-08-15 | 2002-02-21 | Cpd Llc | Method of treating the syndrome of type 2 diabetes in humans |
| US6969712B2 (en) | 2000-11-15 | 2005-11-29 | Banyu Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| US7053101B2 (en) | 2001-04-10 | 2006-05-30 | Alfonzo Jordan | 1,3,8-triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
| US6777421B2 (en) | 2001-04-10 | 2004-08-17 | Ortho-Mcneil Pharmaceutical, Inc. | 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
| US7939670B2 (en) | 2001-04-18 | 2011-05-10 | Purdue Pharma L.P. | Nociceptin analogs |
| US6861421B2 (en) | 2001-04-18 | 2005-03-01 | Euro-Celtique S.A | Nociceptin analogs |
| US7495109B2 (en) | 2001-04-18 | 2009-02-24 | Purdue Pharma L.P. | Nociceptin analogs |
| US6867222B2 (en) | 2001-04-18 | 2005-03-15 | Euro-Celtique, S.A. | Nociceptin analogs |
| US6872733B2 (en) | 2001-04-18 | 2005-03-29 | Euro-Celtique S.A. | Benzimidazolone compounds |
| US6828440B2 (en) | 2001-04-18 | 2004-12-07 | Euro-Celtique, S.A. | Spiroindene and spiroindane compounds |
| US6635653B2 (en) | 2001-04-18 | 2003-10-21 | Euro-Celtique S.A. | Spiropyrazole compounds |
| EP1385515A4 (en) * | 2001-04-18 | 2004-06-30 | Euro Celtique Sa | Spiropyrazole compounds |
| US7563809B2 (en) | 2001-04-18 | 2009-07-21 | Purdue Pharma, L.P. | Nociceptin analogs |
| EP1385515A1 (en) * | 2001-04-18 | 2004-02-04 | Euro-Celtique S.A. | Spiropyrazole compounds |
| EP1402899A1 (en) * | 2001-05-08 | 2004-03-31 | Toray Industries, Inc. | Remedies for sepsis |
| US7652025B2 (en) | 2001-05-08 | 2010-01-26 | Toray Industries, Inc. | Remedies for sepsis |
| EP1402899A4 (en) * | 2001-05-08 | 2009-03-11 | Toray Industries | Remedies for sepsis |
| WO2002100861A1 (en) * | 2001-06-13 | 2002-12-19 | Akzo Nobel N.V. | 1-(3-phenyloxypropyl)piperidine derivatives |
| WO2003082333A1 (en) | 2002-03-29 | 2003-10-09 | Mitsubishi Pharma Corporation | Remedy for sleep disturbance |
| US8003669B2 (en) | 2002-03-29 | 2011-08-23 | Mitsubishi Tanabe Pharma Corporation | Remedy for sleep disturbance |
| US7125877B2 (en) | 2002-05-14 | 2006-10-24 | Banyu Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| US6995168B2 (en) | 2002-05-31 | 2006-02-07 | Euro-Celtique S.A. | Triazaspiro compounds useful for treating or preventing pain |
| US7414062B2 (en) | 2002-05-31 | 2008-08-19 | Purdue Pharma L.P. | Triazaspiro compounds useful for treating or preventing pain |
| US7582649B2 (en) | 2002-09-09 | 2009-09-01 | Janssen Pharmaceutica, Nv | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
| EA009369B1 (en) * | 2002-09-09 | 2007-12-28 | Янссен Фармацевтика, Н.В. | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders |
| US7081463B2 (en) | 2002-09-09 | 2006-07-25 | Janssen Pharmaceutica N.V. | Hydroxy alkyl substituted 1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1receptor mediated disorders |
| WO2004022558A2 (en) * | 2002-09-09 | 2004-03-18 | Janssen Pharmaceutica, N.V. | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders |
| WO2004022558A3 (en) * | 2002-09-09 | 2004-05-21 | Janssen Pharmaceutica Nv | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders |
| US8778956B2 (en) | 2002-09-09 | 2014-07-15 | Janssen Pharmaceutica Nv | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
| WO2004104004A2 (en) * | 2003-05-23 | 2004-12-02 | Zealand Pharma A/S | Triaza-spiro compounds as nociceptin analogues and uses thereof |
| WO2004104004A3 (en) * | 2003-05-23 | 2005-03-03 | Zealand Pharma As | Triaza-spiro compounds as nociceptin analogues and uses thereof |
| US8354434B2 (en) | 2006-01-30 | 2013-01-15 | Purdue Pharma L.P. | Cyclourea compounds as calcium channel blockers |
| US8445508B2 (en) | 2006-10-20 | 2013-05-21 | Neurendo Pharma, Llc | Method of restoring the incretin effect |
| US8785469B2 (en) | 2006-10-20 | 2014-07-22 | Neurendo Pharma, Llc | Method of treating atherogenic dyslipidemia |
| US8399474B2 (en) | 2006-10-20 | 2013-03-19 | Neurendo Pharma, Llc | Method of restoring the incretin effect |
| US8829018B2 (en) | 2006-10-20 | 2014-09-09 | Neurendo Pharma, Llc | Method of restoring the incretin effect |
| US8703948B2 (en) | 2006-11-28 | 2014-04-22 | Janssen Pharmaceutica Nv | Salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one |
| US8741916B2 (en) | 2007-04-09 | 2014-06-03 | Janssen Pharmaceutica Nv | 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the ORL-1 receptor |
| WO2011160084A1 (en) * | 2010-06-18 | 2011-12-22 | Altos Therapeutics, LLC | D2 antagonists, methods of synthesis and methods of use |
| CN103052636A (en) * | 2010-06-18 | 2013-04-17 | 阿尔托斯治疗有限责任公司 | D2 antagonists, methods of synthesis and methods of use |
| US8691836B2 (en) | 2010-06-18 | 2014-04-08 | Altos Therapeutics, LLC | D2 antagonists, methods of synthesis and methods of use |
| US9156840B2 (en) | 2010-06-18 | 2015-10-13 | Altos Therapeutics, LLC | D2 antagonists, methods of synthesis and methods of use |
| CN103052636B (en) * | 2010-06-18 | 2016-03-09 | 阿尔托斯治疗有限责任公司 | D 2antagonist and synthetic method thereof and using method |
| EP3138841A1 (en) * | 2010-06-18 | 2017-03-08 | Altos Therapeutics, LLC | D2 antagonists, methods of synthesis and methods of use |
| US10034871B2 (en) | 2014-11-07 | 2018-07-31 | Regents Of The University Of Minnesota | Salts and compositions useful for treating disease |
| US11472777B2 (en) * | 2015-09-14 | 2022-10-18 | The National Institute for Biotechnology in the Negev Ltd. | Piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1080091A1 (en) | 2001-03-07 |
| JP2002515503A (en) | 2002-05-28 |
| AU3809999A (en) | 1999-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1080091A1 (en) | Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes | |
| AU2001249281B2 (en) | Spiropiperidine derivatives as melanocortin receptor agonists | |
| EP2064192B1 (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
| US6277991B1 (en) | 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes | |
| KR100667645B1 (en) | Cyclic amine ccr3 antagonists | |
| JP2903040B2 (en) | Uses of pyrazolopyridine compounds | |
| KR20150028971A (en) | Solid forms of an antiviral compound | |
| JP2000508334A (en) | Pyrazinone thrombin inhibitors | |
| JPH09507216A (en) | 5- (2-Imidazolinylamino) benzimidazole derivatives, their preparation and their use as α-2-adrenoceptor agonists | |
| NL8701682A (en) | METHOD FOR THE THERAPEUTIC USE OF SEROTONIN ANTAGONISTS, ACTIVE COMPOUNDS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS | |
| JP2002520382A (en) | Diacylhydrazine derivatives as integrin inhibitors | |
| CA2292480A1 (en) | (+)-norcisapride useful for 5-ht3 and 5-ht4 mediated disorders | |
| EP0680323B1 (en) | Synergising association having an antagonist effect on nk1 and nk2 receptors | |
| RO119617B1 (en) | Indazolecarboxamide derivatives, process for preparing the same and pharmaceutical composition | |
| AU714523B2 (en) | Chromone derivatives | |
| KR100384261B1 (en) | Naphthyloxyacetic acid derivative | |
| WO2001036418A1 (en) | Novel triazaspirodecanones with high affinity for opioid receptor subtypes | |
| KR20050119673A (en) | Chromenone indoles | |
| WO2003057214A1 (en) | Imidazolidin-2,4-dione derivatives as non-peptide somatostatin receptor ligands | |
| EP0348564A1 (en) | Orally active antiandrogens | |
| SK15002000A3 (en) | Methods for inhibiting mrp1 | |
| US5561113A (en) | New pseudopeptide compounds of neurokinins | |
| EP3753924A1 (en) | New tricyclic 5-ht2 antagonists | |
| KR100881040B1 (en) | Medicinal composition | |
| WO1999044627A1 (en) | Use of hexapeptides for the manufacture of a pharmaceutical composition for the treatment of hot flushes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 1999920561 Country of ref document: EP |
|
| NENP | Non-entry into the national phase |
Ref country code: KR |
|
| WWP | Wipo information: published in national office |
Ref document number: 1999920561 Country of ref document: EP |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1999920561 Country of ref document: EP |